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ABSTRACT
Optimization Problems in Radiation Therapy Treatment Planning
by
Troy Long
Chairs: Edwin Romeijn, Marina Epelman
Radiation therapy is one of the most common methods used to treat many types of cancer.
External beam radiation therapy and the models associated with developing a treatment
plan for a patient are studied. External beams of radiation are used to deliver a highly
complex so-called dose distribution to a patient that is designed to kill the cancer cells while
sparing healthy organs and normal tissue. Treatment planning models and optimization are
used to determine the delivery machine instructions necessary to produce a desirable dose
distribution. These instructions make up a treatment plan. This thesis studies four problems
in radiation therapy treatment plan optimization.
First, treatment planners generate a plan with a number of competing treatment plan
criteria. The relationship between criteria is not known a priori. A methodology is de-
veloped for physicians and treatment planners to efficiently navigate a clinically relevant
region of the Pareto frontier generated by trading off these different criteria in an informed
way. Second, the machine instructions for intensity modulated radiation therapy, a com-
mon treatment modality, consist of the locations of the external beams and the non-uniform
intensity profiles delivered from each of these locations. These decisions are traditionally
made with separate, sequential models. These decisions are integrated into a single model
and propose a heuristic solution methodology. Third, volumetric modulated arc therapy
(VMAT), a treatment modality where the beam travels in a coplanar arc around the pa-
tient while continuously delivering radiation, is a popular topic among optimizers studying
treatment planning due to the difficult nature of the problem and the lack of a universally
accepted treatment planning method. While current solution methodologies assume a pre-
determined coplanar path around the patient, that assumption is relaxed and the generation
xiii
of a non-coplanar path is integrated into a VMAT planning algorithm. Fourth, not all
patient information is available when developing a treatment plan pre-treatment. Some in-
formation, like a patient’s sensitivity to radiation, can be realized during treatment through
physiological tests. Methodologies of pre-treatment planning considering adaptation to new
information are studied.
xiv
CHAPTER I
Introduction
1.1 Radiation Therapy Treatment Planning
Radiation therapy is one of the most common methods used to treat many different
types of cancer. There are different techniques for exposing cancerous tissue to radiation,
and in these studies we will be investigating external beam radiation therapy. With this
technique, external beams of radiation are used to deliver a highly complex so-called dose
distribution to a patient that is designed to kill the cancer cells while sparing healthy organs
and normal tissue. Treatment planning models and optimization are used to determine the
delivery machine instructions necessary to produce a desirable dose distribution. This thesis
will focus on models that address some of the shortcomings with current treatment planning
and offer clinically applicable techniques for solving these problems.
After a patient is diagnosed with cancer, a physician will determine the patient’s course
of treatment (see Figure 1.1). If radiation therapy is included in this treatment, a patient
will have detailed imaging performed to allow treatment planners to construct a 3D model
of the patient within a treatment planning system, a software package that assists treatment
planners in determining machine instructions for delivery. After imaging, a physician will
manually contour each critical structure and target within the patient. The system then
uses this geometric information to simulate radiation delivered to the patient to estimate
the effects of delivering radiation from a certain angle at a certain intensity. This information
will be used to relate machine instructions to dose received by the patient. After the machine
instructions and corresponding dose distribution are decided upon by the physician and the
treatment planner, the patient is treated. Patients receive radiation over a number of days,
each session delivering a portion of the total treatment. These sessions are referred to as
fractions. During these fractions, new patient information may be observed and prompt
adapting the plan to the new information. After the patient completes a full course of
treatment fractions, the patient is imaged and the diagnosis is reassessed.
1
Figure 1.1: Illustration of the stages a patient goes through from diagnosis to treatment
The main treatment modalities we consider are intensity modulated radiation ther-
apy (IMRT) and volumetric modulated arc therapy (VMAT). In both modalities, radia-
tion is delivered through the rectangular opening on the gantry and through an multileaf
collimator (MLC) (see Figure 1.2) that uses sliding tungsten leaves to block radiation and
form shapes called apertures. IMRT utilizes a fixed number of stationary beam locations to
deliver radiation through multiple apertures of varying intensity at each location of varying
intensities. The primary decisions that are needed to define an IMRT treatment plan are
the beam directions, aperture shapes, and aperture intensities. VMAT, a more advanced
and modern modality, employs a beam that rotates in an arc continuously with dynamically
changing apertures and intensity (see Figure 1.2). The primary decisions that are needed to
define a VMAT treatment plan are the MLC leaf positions along the arc, the dose rate, and
the speed of the gantry.
Figure 1.2: (left) Sliding leaves in a multi-leaf collimator, (right) VMAT treatment delivery
machine, gantry ghosting through delivery arc (photo credits to Varian Medical Systems)
2
1.2 Traditional Treatment Planning Models
We present the general structure of treatment plan optimization models for IMRT without
the project-specific minutiae. The VMAT treatment planning model only applies to chapter
IV and thus will not be included here. Clinically motivated changes to these models as well
as corresponding solution methodologies will be explored in the following chapters.
As stated earlier, the decisions to be made in IMRT are the beam directions, aperture
shapes, and aperture intensities. Of these decisions, let us assume that the beam directions
are selected and fixed through some process (see chapter III). The remaining decisions are
the aperture shapes and aperture intensities. There are two main ways to model and solve
for these values: fluence map optimization (FMO) followed by leaf sequencing (LS) and
direct aperture optimization (DAO). FMO generates a non-uniform intensity profile for each
beam and the post-processing LS step generates the apertures and corresponding intensities
necessary to deliver a plan that produces a dose distribution close to that generated by
the original FMO intensity profile. DAO is an iterative procedure that actively generates
deliverable apertures to be used in the treatment planning model.
There is a core set of notation that will be used throughout this thesis. We present
that notation here, and any deviations or additions will be updated within the associated
chapters. Common to all presented treatment planning models, the patient geometry is
discretized into small volumes called voxels represented by set V . Let zj be the dose received
by voxel j ∈ V . Let B be the set of potential discrete beam locations around the body.
1.2.1 Fluence Map Optimization
In FMO, we need to define the sets of beam locations and beamlets. Let B′ be the set of
active (i.e., used in the treatment plan) beam locations. These locations can be in a coplanar
arc around the patient or in a non-coplanar arrangement. Non-coplanar arrangements are
often referred to as the 4pi space around a patient. In order to represent the FMO intensity
profile, each beam b ∈ B′ is discretized into a grid of beamlets Nb. Let decision variable xbi be
the intensity for beamlet i ∈ Nb for beam b ∈ B′. Sometimes beamlet intensity is presented
as xi for i ∈ N when beam-specificity is not relevant to the problem (i.e., i ∈ N = ∪b∈B′Nb).
To relate the beamlet intensities to the voxel doses, let Dbij be the dose delivered to voxel
j ∈ V from beamlet i ∈ Nb in beam b ∈ B′ at unit intensity. With objective function F (z),
representing treatment plan evaluation criteria as a function of dose, and set of deliverable
treatment plans Z, we can construct the basic FMO model as follows:
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minimize
x,z
F (z) (1.1)
subject to zj =
∑
b∈B′
∑
i∈Nb
Dbijxbi ∀j ∈ V (1.2)
z ∈ Z (1.3)
xbi ≥ 0 ∀b ∈ B′,∀i ∈ Nb. (1.4)
LS occurs after FMO to generate apertures and aperture intensities. For the purposes
of this thesis, LS is assumed to occur without incident and thus is not considered when
modeling using FMO (see Xia and Verhey , 1998 for more information on LS).
1.2.2 Direct Aperture Optimization
In DAO, the variables of aperture intensities are directly represented in the model. Let
Ab be the set of deliverable apertures on beam b ∈ B′ and let ybk be the intensity of aperture
k ∈ Ab on beam b ∈ B′. To relate aperture intensity to dose received, let Dbkj be the dose
delivered to voxel j ∈ V from aperture k ∈ Ab at beam b ∈ B′. The full treatment planning
model looks as follows:
minimize
y,z
F (z) (1.5)
subject to zj =
∑
b∈B′
∑
k∈Ab
Dbkjybk ∀j ∈ V (1.6)
z ∈ Z (1.7)
ybk ≥ 0 ∀b ∈ B′,∀k ∈ Kb. (1.8)
While the model structure seems similar to the FMO model, there are many more deliv-
erable apertures than beamlets for each beam (i.e., |Nb| << |Ab|). Therefore, sophisticated
solution methodologies are used to solve this problem (see, e.g., Romeijn et al., 2005 for
a column-generation approach). Sometimes the b ∈ B′ subscript is dropped when beam-
specificity is not needed. Due to the large number of Dkj values, Dkj values are constructed
as needed using a beamlet approximation. Let i ∈ Nk be the set of beamlets that make up
aperture k ∈ A. We can then calculate Dkj as the following for all k ∈ A and j ∈ V :
Dkj =
∑
i∈Nk
Dij. (1.9)
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1.2.3 Modeling Criteria
As mentioned before, the main goals of radiation therapy treatment planning are to de-
liver a dose distribution that eradicates the cancerous tissue while sparing healthy tissue
and functioning organs. In the treatment planning models in Section 1.2, the objective of
the models is some function of dose, F (z). How F (z) is constructed, however, is not a well-
established, clear procedure in the clinic. There are a multitude of treatment plan evaluation
functions used to describe the effects of radiation in the body. There are functions that give
probabilities of control or complications for tumors and non-cancerous tissue, respectively.
Some examples include tumor control probability (TCP) and normal tissue complication
probability (NTCP) (see, e.g., Webb and Nahum, 1993; Warkentin et al., 2004; Marks et al.,
2010). Other criteria include voxel-based evaluation functions and dose-volume functions
(see Shepard et al., 1999 for an overview), metrics that convert non-uniform dose to a struc-
ture to the radiobiologically equivalent uniform dose (see equivalent uniform dose (EUD) in
Niemierko, 1999), and proxy metrics for some of those listed earlier (e.g., conditional value-
at-risk (CVaR) in Romeijn et al., 2003 and linearized EUD in Thieke et al., 2002). Some
are “easy” objectives (e.g., piecewise quadratic voxel-based penalties are convex) while oth-
ers are extremely difficult to incorporate explicitly into the treatment planning model (e.g.,
dose-volume objectives are non-convex).
On top of it being unclear which functions to use in the objective, the relative importance
of different objectives is also unclear a priori (see chapter II for more information). Multiple
objectives will be given for planners to improve upon or satisfy, but how these competing
objectives behave is not immediately clear. Traditionally, physicians and treatment planners
work together in an iterative, trial-and-error fashion to select a combination of evaluation
functions and relative importances to arrive at a desirable treatment plan.
1.3 Chapter Summaries
1.3.1 Sensitivity Analysis in Lexicographic Ordering, Chapter II
When presented with a radiation therapy case, physicians approach the treatment plan-
ning process with a number of goals for the treatment outcome of varying importance. For
example, sparing the brainstem of lethal radiation will be much more critical than reducing
hotspots in normal tissue surrounding the brainstem. In this process, the physicians develop
a hierarchy of criteria they believe to be significant in determining a treatment plan. Two
questions arise when considering different criteria of unclear relative importance. First, what
tradeoff information between competing objectives in the model might prove beneficial to
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treatment planners and physicians? Sometimes yielding a small amount on the most im-
portant treatment goals may provide significant benefits in overall treatment plan quality,
and identifying this tradeoff can be non-trivial. Second, how can these tradeoffs be calcu-
lated efficiently and presented in a manner valuable to physicians? Because the calculations
necessary to produce accurate representations of these relationships could be lengthy, tech-
niques to quicken the process without losing accuracy can help maintain clinical feasibility.
We address both of these questions in chapter II, as well as a several improvements that
increase the efficiency of the initially developed methodology. To improve the methodology,
we incorporate additional bounds on the relevant region of the generated Pareto frontier and
automate some of the proposed interactive steps.
1.3.2 Beam Orientation Optimization, Chapter III
In IMRT beam orientation optimization, a small number of beam positions must be iden-
tified that allow for both high treatment plan quality and efficient deliverability, creating a
large-scale combinatorial optimization problem. Traditionally, beam selection and FMO are
approached as separate, sequential models. We integrate these models and develop efficient
and effective methods for selecting high-quality coplanar or non-coplanar beam orientations
for IMRT treatments. The proposed methods explicitly incorporate the effects of beam se-
lection on the quality of the resulting optimal dose distribution. To this end, we propose a
greedy heuristic framework for solving the integrated model. The algorithm iteratively adds
beams to the model according to a dynamically updated attractiveness measure for each
remaining candidate beam. We consider measures that are based explicitly on the optimal
dose distribution corresponding to the currently selected set of beams. Several specific at-
tractiveness measures are proposed that use either first-order or both first and second-order
information. Performance of the algorithm is assessed on clinical data demonstrating a high
quality dose distributions found with fewer beams than traditional methods. Theoretical
work is also presented aimed at finding methods for bounding optimal solutions to the in-
tegrated beam orientation optimization and fluence map optimization treatment planning
model.
1.3.3 Non-coplanar Volumetric Modulated Arc Therapy, Chapter IV
VMAT is rapidly emerging as a method for delivering radiation therapy treatments to
cancer patients that are of comparable quality to IMRT but much more efficient. In VMAT,
the beam moves along a coplanar arc (i.e., fixed couch position with a moving gantry) while
delivering radiation through dynamically changing apertures. The decisions here are the
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(usually fixed) coplanar arc path, the movements of the MLC along the arc, the speed of
the gantry, and the dynamic dose rate of the beam. When making these decisions, we
must consider machine constraints such as MLC leaf movement restrictions, dose rate limits,
and gantry acceleration bounds. The next step in taking advantage of the flexibility of the
delivery machines is to consider non-coplanar paths in the 4pi space around the patient as
well. We propose a constructive approach that employs both column generation and routing
heuristics to simultaneously determine the non-coplanar path of the beam, MLC movements,
and dose rate. A proof-of-concept implementation is presented on a brain cancer case.
1.3.4 Adaptive Treatment Planning for Lung Cancer, Chapter V
When developing a personalized treatment, planners use a physician’s treatment plan-
ning goals based on patient information obtained pre-treatment. However, over the course
of treatment these patient characteristics may change, evolving the planner’s initial under-
standing of patient characteristics and causing inaccuracies in the treatment plan. The
pre-treatment plan is often reoptimized mid-treatment to these new data. For example,
certain biomarker data obtained during treatment after several fractions of radiation have
been delivered has been shown to be predictive of a patient’s predisposition to radiation-
induced lung toxicity. We develop several methodologies for pre-treatment planning when
adaptation is likely to occur. A two-stage stochastic treatment plan optimization model to
explicitly consider future patient-specific biomarker information is developed along with a
less-computationally-intensive heuristic methodology. Recommendations for building flexi-
bility for future adaptation into initially-delivered dose distributions are presented.
Research Collaborators Chapter-specific acknowledgement sections will identify research
collaborators for each project.
Research Funding All projects partially supported by NSF GRFP between 2012 and
2015. Funding for projects in Chapters II and V partially from grant number NIH-P01-
CA59827. Two Rackham Student Research Grants were awarded for partial support on
Chapters III (2012) and IV (2014).
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CHAPTER II
Sensitivity Analysis in Lexicographic Ordering for
Radiation Therapy Treatment Planning
This chapter discusses a project we worked on in 2010-2012. This project allowed us
to get into both the modeling side of radiation therapy treatment planning as well as the
computational aspects of treatment plan optimization. Sections 2.1 to 2.3 of the following
text is largely pulled from the paper published in Medical Physics (see Long et al., 2012) along
with some additional work done with a few undergraduate student researchers in Section 2.4.
2.1 Introduction
When addressing a radiation therapy case, a physician generally presents the treatment
planner with a number of dosimetric goals of varying importance. Although the general
objective is to deliver a prescribed radiation dose to the target(s) while simultaneously
sparing critical structures, a major challenge remains how to make the unavoidable tradeoffs
between these conflicting goals. The literature on radiation therapy treatment planning
contains a multitude of evaluation criteria that can be used to quantify various properties of
a treatment plan. Because treatment planning is generally a time-consuming endeavor which
has to be performed for individual patients, providing a treatment planner with tools that
allow for an efficient assessment of the interplay and tradeoffs between conflicting treatment
plan evaluation criteria is essential to an efficient and effective treatment planning process.
Traditionally, radiation therapy treatment planning is based on optimization models
containing a single objective function to be optimized subject to a set of hard constraints on
the treatment plan. The objective function is typically a simple weighted sum of individual
treatment plan evaluation criteria (see Breedveld et al., 2009). Since there is no formal basis
for choosing a priori values for these weights, their values are usually updated manually
by the treatment planner in an iterative fashion in order to arrive at a clinically desirable
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treatment plan. Occasionally this method yields acceptable results quickly, but in general
this approach is inefficient and may lead to inferior treatment plans.
A modern technique for exploring the tradeoffs between treatment plan evaluation criteria
is based on multi-criteria optimization (MCO) (see, e.g., Ku¨fer et al., 2009 for a recent
overview of this area). In this approach, the goal is to approximate the Pareto frontier
containing all efficient treatment plans, i.e., treatment plans with the property that it is not
possible to improve the plan with respect to one of the criteria without deteriorating the plan
with respect to at least one other. While there are many methods for generating this frontier
(see, e.g., Ruzika and Wiecek , 2005), a common technique is to solve a sequence of single-
objective optimization problems, each using an appropriately chosen set of weights for the
individual criteria. When all criteria are convex functions of the dose distribution delivered to
the patient, each of the corresponding solutions will represent a point on the Pareto frontier.
If the number of such solutions is large enough to allow the Pareto frontier to be accurately
approximated (typically using interpolation), the treatment planner can assess the tradeoffs
between competing objectives by navigating the frontier and use this information to select a
treatment plan. Using MCO as a means of quantifying tradeoffs is conceptually attractive, in
the sense that it provides the treatment planner with complete and comprehensive tradeoff
information on all criteria. However, the number of competing criteria can be large (say,
on the order of 10–25 in a typical clinical setting), which means that the Pareto frontier
is embedded in a correspondingly high-dimensional space. Many solutions may then be
required to accurately approximate the Pareto frontier, which reduces the efficiency of the
methodology (see Hong et al., 2008). Moreover, visualizing and interpreting the plethora of
tradeoffs can prove difficult (see Craft and Monz , 2010). Of course a reduction in the number
of criteria or data reduction in the form of a coarser representation of patient geometry
and/or capabilities of the delivery equipment may mitigate these drawbacks, but this may
affect the accuracy of the frontier or the quality of the tradeoff information (see, e.g., Craft
and Bortfeld , 2008).
A key observation is that the full Pareto frontier identified by MCO will likely contain
many tradeoff regions that are clinically unacceptable or irrelevant. This not only compli-
cates the navigation process as outlined above, it also means that a large amount of time
may be spent identifying such uninteresting tradeoffs. It therefore seems appropriate to
explicitly incorporate better a priori clinical information on priorities associated with the
different criteria into the treatment plan optimization process. One such approach is lexico-
graphic optimization (LO), which is sometimes also referred to as prioritized optimization
(see Wilkens et al., 2007; Jee et al., 2007; Clark et al., 2008). This is a multi-stage approach
that is based on a complete ranking or prioritization of treatment planning goals. In its
9
purest form it starts by optimizing the highest ranked criterion. The optimal value to this
problem is then used to constrain the value of the corresponding criterion in subsequent
optimization models. In particular, in the following stage the second criterion on the pri-
oritized list is optimized subject to the value of the first criterion being optimal. Following
that, the third is optimized subject to the value of the first and second criteria’s solutions
from the previous model. This approach is then continued for each criterion on the list, and
the solution to the final optimization problem in the sequence is the optimal treatment plan
with respect to the prioritized list of criteria. LO is computationally efficient and provides a
clear, systematic approach. In contrast with MCO, LO does not rely on interaction with the
treatment planner (once the prioritization is fixed). However, much flexibility is sacrificed in
the wake of the computational and structural benefits. In particular, a notable drawback of
using an LO approach is that the treatment planner may be unaware of opportunities that
may exist to improve a treatment plan. In terms of MCO, the LO approach can be inter-
preted as confining the treatment planner’s view to a specific extreme solution on the full
Pareto frontier of inter-criterion tradeoffs. If a minor sacrifice in high-priority criteria could
yield meaningful benefits with respect to lower-priority criteria, the pure LO approach would
not recognize or identify this opportunity. In order to introduce some flexibility into the pro-
cess one might relax the optimality constraint on high-priority criteria and instead require
previously optimized criteria to remain “near-optimal.” Since tradeoffs are not characterized
and assessed explicitly, it is not clear how to quantify the concept of near-optimality, nor
how to predict the consequences of allowing a deviation from optimality. In contrast, our
method will provide an interactive way for the user to select the relaxation based on a formal
sensitivity analysis.
In this chapter, we propose a systematic approach, sensitivity analysis in lexicographic
ordering (SALO), which combines the benefits of MCO (flexibility and comprehensiveness)
and LO (efficiency and clinical focus) while avoiding their pitfalls. Similar to LO, it incor-
porates clinical information through a prioritized list of treatment plan evaluation criteria.
However, in contrast with LO, it uses this information to efficiently navigate a clinically in-
teresting and relevant segment of the Pareto efficient frontier in an interactive and iterative
fashion. In Section 2.2 of this chapter we will provide a formal and detailed description of the
SALO approach. In Section 2.3 we will then illustrate the approach on two clinical cases and
discuss the performance of the algorithm. In Section 2.4 we will discuss some improvements
made to the model and conclude in Section 2.5.
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2.2 Model and Methodology
The goal of the SALO approach is to provide local information on the shape of the Pareto
frontier to treatment planners for use as a decision making aid, based on clinical preferences
represented via a prioritized list of treatment plan evaluation criteria. This local information
takes the form of a two-dimensional Pareto frontier that, in each stage, characterizes the
tradeoff between two consecutive criteria while (i) constraining higher priority criteria to
values that have been established earlier in the process; and (ii) temporarily ignoring lower
priority criteria. The treatment planner can then examine this tradeoff curve and select
a point that appropriately captures the tradeoff between the two criteria currently under
consideration. This point then defines a bound for the criterion that has the higher priority.
2.2.1 Bi-criteria Treatment Planning Model
Optimization models for radiation therapy treatment planning are usually classified as
“beamlet-based” (yielding an optimal fluence map, which subsequently needs to be converted
into a deliverable plan in a leaf-sequencing stage) and “aperture-based.” We have chosen
to use the latter, DAO, approach (see, e.g., Shepard et al., 2002; Preciado-Walters et al.,
2004; Romeijn et al., 2005; Men et al., 2007) since it not only eliminates the need for a leaf-
sequencing stage but can also allow for a more efficient implementation and solution since an
instance of the DAO model is typically much smaller and hence can be solved more rapidly
than an instance of a beamlet-based FMO problem. This is particularly important since
many of these problem instances will need to be solved during the course of the SALO pro-
cedure. However, if desired, the general SALO approach can be applied to a more traditional
FMO model with only minor modifications.
The notation in this chapter is consistent with notation presented in 1.2.1. For simplicity,
we will let y = (yk : k ∈ A) and z = (zj : j ∈ V) denote the corresponding vectors. Convex-
ity of the set of feasible treatment plans, Z, is important for tractability of our approach,
and we usually expect this set to contain only simple lower and upper bound constraints on
the individual voxel doses. In principle other hard constraints on treatment plan evaluation
criteria could be included as well, although we envision those tradeoffs to be made in the
actual SALO procedure rather than by a priori excluding certain dose distributions.
The treatment plan evaluation criteria are given as functions of the dose distribution:
G` : R|V| → R (` = 1, . . . , L + 1), where we assume that the criteria are indexed in order
of decreasing priority. For mathematical convenience we will assume that these criteria
are such that smaller values are preferred to larger values. In addition, we will generally
assume that they are all convex functions. Note that, in a multicriteria context, many
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common treatment plan evaluation criteria, such as voxel-based penalty functions, EUD,
generalized equivalent uniform dose (gEUD), TCP, NTCP, or CVaR, are either convex
or can equivalently be replaced by convex ones (see Romeijn et al., 2004). Our proposed
approach could in principle be generalized to accommodate a nonconvex set Z and/or truly
nonconvex criteria, such as traditional Dose-Volume Histogram (DVH) constraints, albeit at
the expense of computational efficiency. The last criterion, GL+1, is typically chosen in order
to minimize total dose delivered to the patient while maintaining treatment plan quality
with respect to all previously considered criteria. The SALO approach then interactively
searches for a treatment plan by solving a sequence of bi-criteria optimization models of the
following form (for ` = 1, . . . , L), referred to as stages of the procedure:
minimize
(y,z)
{G`(z), G`+1(z)}
subject to (P(`))
zj =
∑
k∈A
Dkjyk for j ∈ V (2.1)
G`′(z) ≤ G`′ for `′ = 1, . . . , `− 1 (2.2)
yk ≥ 0 for k ∈ A (2.3)
z ∈ Z, (2.4)
where G`′ is an upper bound on treatment plan evaluation criterion G`′ that is set in the
earlier stage `′ of the procedure by solving the prior bi-criteria optimization problem (P(`
′))
(for `′ = 1, . . . , `− 1) and making the corresponding tradeoff.
Due to the convexity of the criterion functions, the solution to the bi-criteria optimiza-
tion problem (P(`)) can be found by solving single-criterion optimization problems with an
objective function of the form:
αG`(z) + (1− α)G`+1(z), (2.5)
for all α ∈ [0, 1].
2.2.2 Sensitivity Analysis in Lexicographic Optimization Methodology
If the set of all deliverable apertures were manageable we could directly apply the ap-
proach outlined above. Unfortunately, in general the cardinality of the set A is very large
and the optimization problems (P(`)) cannot be solved explicitly. One potential approach
would be to generate high-quality apertures “on the fly” according to a column genera-
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tion approach that has been proposed for solving single-criterion DAO problems (see, e.g.,
Preciado-Walters et al., 2004; Romeijn et al., 2005; Men et al., 2007)). However, this would
mean that the set of apertures considered in later stages of the algorithm is different from (in
fact, larger than) the set of apertures allowed in earlier stages. This means that the tradeoffs
between the higher priority, and hence clinically more important, criteria are based on a
more limited set of apertures. Intuitively it would seem more attractive to base the more
important (or, in fact, all) tradeoff decisions on the most accurate representation of the op-
timization model rather than the least accurate, which makes a straightforward application
of this idea undesirable.
In order to address this issue we propose to start the SALO procedure with an initial phase
in which a high-quality pool of apertures is generated, which is then kept fixed throughout the
L stages of the SALO procedure. This does not only improve the computational efficiency
of the approach, but also ensures that all decisions are made based on consistent input
and information. However, it is clear that, in this process, the tradeoff decisions are not
made with respect to the full information regarding all deliverable apertures. We therefore
also propose a final phase in which a full DAO model is solved to identify a new set of
apertures that minimizes the last criterion, GL+1, subject to all bounds imposed on criteria
G1, . . . , GL. Clearly, this final phase could also take other considerations, such as treatment
delivery efficiency, into account. In summary, we propose a SALO procedure that proceeds
in three phases:
Sensitivity Analysis in Lexicographic Optimization
Phase 1. Generation of a clinically relevant aperture pool of computationally manageable
cardinality.
Phase 2. Generation of patient-specific treatment planning goals G` (` = 1, . . . , L) by
solving a sequence of bi-criteria optimization problems (P(1)), . . . , (P(L−1)).
Phase 3. Generation of final treatment plan that satisfies the patient-specific treatment
planning goals while minimizing an overall single objective function.
In the remainder of this section we will discuss these three stages in more detail.
2.2.2.1 Aperture Pool Generation
We generate an aperture pool by solving a traditional single-criterion treatment plan
optimization model based on the treatment plan evaluation criteria:
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minimize
(y,z)
L∑
`=1
α`G`(z)
subject to (P)
zj =
∑
k∈A
Dkjyk for j ∈ V (2.6)
yk ≥ 0 for k ∈ A (2.7)
z ∈ Z, (2.8)
where α` ≥ 0 (` = 1, . . . , L) are nonnegative criterion weights. The set of weights used in the
aperture generation phase could be based on experience with other, similar, patient cases.
Alternatively, we could use a sequence of criterion weights, allowing for the generation of
apertures that are attractive with respect to a variety of tradeoffs. We will denote the set of
apertures in the pool by A.
2.2.2.2 Solving the Bi-criterion Optimization Problem
We use the so-called Sandwich Algorithm (see, e.g., Hoffmann et al., 2006; Ku¨fer et al.,
2009; Ehrgott et al., 2010) to approximate the Pareto frontier at a given stage of the SALO
procedure. This algorithm, which tries to balance clinical accuracy and computational ef-
ficiency, applies when all treatment plan evaluation criteria are convex, and is particularly
efficient in the bi-criteria case. The idea behind this algorithm is to approximate the entire
Pareto frontier by constructing both an upper (“conservative”) and a lower (“optimistic”)
bound on the frontier based on a finite set of points on the frontier. This is done by solving a
sequence of optimization problems of the form (P(`)) with objective function of the form (2.5)
for different values of α. The optimal solutions to these problems yield points on the Pareto
frontier. For convenience, let z∗(α; `) denote an optimal solution to (P(`)) when parameter
α is used. Then let
G∗`(α; `) = G` (z
∗(α; `)) (2.9)
G∗`+1(α; `) = G`+1 (z
∗(α; `)) (2.10)
G∗`,`+1(α; `) = αG
∗
`(α; `) + (1− α)G∗`+1(α; `). (2.11)
The Sandwich Algorithm then determines upper and lower bounds on the Pareto frontier
as follows:
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Upper bound Using simple linear interpolation of a set of Pareto efficient solutions we
obtain a piecewise-linear and convex function which is well-known to form an upper bound on
the Pareto frontier. This follows immediately from the fact that the line segment connecting
any two points of the form
(
G∗`(α; `), G
∗
`+1(α; `)
)
for different values of α is guaranteed to
be entirely on or above the Pareto frontier. More formally, such a line segment can be
characterized as
{(λG∗`(α′; `) + (1− λ)G∗`(α′′; `), λG∗`+1(α′; `) + (1− λ)G∗`+1(α′′; `)) : λ ∈ [0, 1]} (2.12)
where 0 < α′ 6= α′′ < 1. The sandwich algorithm process can be seen in Figure 2.1 as
an example between the EUD to the bladder and the EUD to the rectum. Each iteration
generates points in between existing points, effectively doubling the precision), and adds
upper bounds on the curve using equation (2.12), shown as piecewise linear functions. The
lower bounds are not shown for simplicity, but the true curve must pass through all generated
points along the curve.
It is interesting to note that due to the convexity of G∗` and G
∗
`+1 we can find an even
better bound on the Pareto frontier by, instead of interpolating the pairs of optimal objec-
tive function values for different values of α, interpolating the optimal treatment plans (or,
equivalently, optimal dose distributions) for different values of α. In other words, the curve
of the form:
{(G` (λz∗(α; `) + (1− λ)z∗(α′; `)) ,
G`+1 (λz
∗(α; `) + (1− λ)z∗(α′; `))) : λ ∈ [0, 1]}, (2.13)
where 0 < α 6= α′ < 1 is guaranteed to not only be entirely on or above the Pareto frontier,
but also entirely on or below the curve in equation (2.12). While the precise values of the
upper bound do not directly factor into our algorithm, we recommend using equation (2.13)
for upper bound estimation.
Lower bound A lower bound can be determined by observing that for some fixed α and
associated G∗`,`+1(α; `) a line given by the following:{
(g`, g`+1) : αg` + (1− α)g`+1 = G∗`,`+1(α; `)
}
, (2.14)
is entirely on or below the Pareto frontier (where (g`, g`+1) denotes a point in R2). As α
changes, lines satisfying this equation lie tangent to the true curve. This follows since (i)
the Pareto frontier is convex by convexity of the criteria functions G` and G`+1; and (ii) the
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point
(
G∗`(α; `), G
∗
`+1(α; `)
)
lies both on the efficient frontier and the line (2.14). This means
that the upper envelope of these lines over a collection of different values of α ∈ (0, 1) is a
piecewise-linear convex function that is entirely on or below the Pareto frontier as well.
Figure 2.1: Example upper bounds generated by the sandwich algorithm
Choosing objective function weights α There are different ways in which the set of
values for α to be used at a particular SALO stage can be determined. In an interactive
implementation, the treatment planner could indicate which value to use with the goal of
refining the approximation of the Pareto frontier in the clinically most relevant or interesting
areas. In an automated setting this can be done by measuring the discrepancy between the
upper and lower bounds, and choosing that value of α where the discrepancy is largest. Since
the bounds are themselves curves, different discrepancy measures can be used, and each of
them will yield a different sequence of values for α and a different bounding of the frontier.
However, with careful design, we can ensure that the lower and upper bounds both converge
to the Pareto frontier as the number of values for α increases (see Craft et al., 2006).
2.2.2.3 Final Treatment Plan Optimization
This full model clearly has a feasible solution (by construction), i.e., by generating a
new set of apertures from scratch we know it will be possible to achieve all previously
identified treatment planning goals. The DAO column generation procedure can therefore
be initialized with the final solution obtained by the SALO procedure. However, if there is
an additional goal related to treatment plan delivery efficiency, such as limiting the beam-
on-time or number of apertures, it may be preferable to discard the original aperture pool
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and start the DAO algorithm from scratch. Since a feasible solution is needed to start the
procedure, the algorithm is then started by first solving an auxiliary problem of the following
form:
minimize
(y,z)
L∑
`=1
max
{
G`(z)−G`, 0
}
subject to (I)
zj =
∑
k∈A
Dkjyk for j ∈ V
yk ≥ 0 for k ∈ A
z ∈ Z.
Any feasible solution to this problem with objective function value 0 is a feasible solution
to the actual problem from which the DAO algorithm can be started.
2.2.3 Treatment Plan Evaluation Criteria
For our experiments we have chosen to use common measures of gEUD for each target
and major critical structure as our main treatment plan evaluation criteria. Letting S denote
the set of structures and Vs the set of voxels in structure s ∈ S, the gEUD corresponding to
the dose distribution in structure s ∈ S is given by the following:
gEUDs(z; as) =
(
1
|Vs|
∑
j∈Vs
zasj
) 1
as
(2.15)
where 1 ≤ as ≤ ∞ if s is a critical structure while −∞ ≤ as ≤ 1 if s is a target, and where
gEUDs(z; as) =

maxj∈Vs zj if as =∞
1
|Vs|
∑
j∈Vs zj if as = 1
minj∈Vs zj if as = −∞,
(see, e.g., Niemierko, 1999; Choi and Deasy , 2002). For the sake of computational efficiency
we have chosen to use an approximation of gEUD given by a convex combination of mean
and maximum dose for critical structures and of mean and minimum dose for targets (see
Craft et al., 2005; Thieke et al., 2002). In particular, we choose treatment plan evaluation
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criteria functions G` of the form:
γsgEUDs(z; 1) + (1− γs)gEUDs(z;∞) = γs
1
|Vs|
∑
j∈Vs
zj + (1− γs) max
j∈Vs
zj (2.16)
if s is a critical structure, and,
γsgEUDs(z; 1) + (1− γs)gEUDs(z;−∞) = γs
1
|Vs|
∑
j∈Vs
zj + (1− γs) min
j∈Vs
zj, (2.17)
if s is a target, where in both cases γs ∈ [0, 1]. (Note that, unlike the generic model, target-
related criteria will be maximized rather than minimized). These gEUD approximations
pertaining to targets are concave, thus taking the negative and minimizing fits into our
generic convex problem formulation. The advantage of using these approximations is that
our optimization problems can be formulated and solved as linear programs.
As our final criterion we have chosen to minimize the sum of all voxel doses:
GL+1(z) =
∑
j∈V
zj. (2.18)
Moreover, we assume that no tradeoff takes place between gEUD-criterion GL and this
final criterion GL+1, so that, in problem (P
(L)), we limit ourselves to α = 1 in the corre-
sponding objective function (2.5).
2.3 Illustration of SALO on Clinical Cases
2.3.1 Data and computations
We illustrate our SALO procedure on two clinical cases from different sites: brain and
prostate. The brain cancer case has 8 beams and 575 beamlets while the prostate cancer case
has 7 beams and 796 beamlets. In both cases the beamlets were of dimension 5 × 5 mm2,
and only beamlets whose primary trajectory intersected with the target(s) were included in
the model. We chose the set Z to be of the form
Z =
{
z ∈ R|V| : zs ≤ zj ≤ zs, j ∈ Vs, s ∈ S
}
, (2.19)
for zs and zs chosen by physicians. The weighting parameters γs in the gEUD-approximation
described in Section 2.2.3 were found by evaluating both the gEUD and its approximation
on a clinically acceptable dose distribution, where suitable values of the gEUD parameters as
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were taken from Burman et al. (1991); Lawrence et al. (2010); Mayo et al. (2010); Michalski
et al. (2010); Roach, III et al. (2010); Viswanathan et al. (2010), and clinical practice at the
University of Michigan Department of Radiation Oncology. Values of γs were tweaked until
the approximate gEUD values from equations (2.16) and (2.17) were the same for the gEUD
values from (2.15) for clinically acceptable dose distributions. Table 2.1 provides, for each of
the two cases, the structures and two prioritization scenarios, as well as the number of voxels
|Vs| in each structure s ∈ S, the gEUD parameters as and γs, and the dose upper and lower
bounds zs and zs (where the latter is 0 if omitted). The structures without prioritization
values will be addressed in the final treatment plan optimization, but not in the interactive
portion of the algorithm.
The optimization problems were all solved on a Mac Pro 4,1 with a single 2.93 GHz Quad-
Core Intel Xeon processor and 12 GB DDR3 memory at 1066 MHz. All model generation
code was written in C++ and executed in Xcode, and the primal simplex method of CPLEX
12.2 was used as the solver. Since the coefficients Dkj are too numerous to be precomputed
and stored, and since the column generation relies on an efficient representation of these
coefficients, we make the common assumption that these coefficients can be expressed in
terms of so-called beamlet-based dose deposition coefficients,
Dkj =
∑
i∈Nk
Dij, (2.20)
where Nk ⊆ N is the subset of beamlets that is exposed in deliverable aperture k ∈ A, N is
a set of beamlets that discretizes the beams used for treatment, and Dij is the dose delivered
to voxel j ∈ V from beamlet i ∈ N at unit intensity. Storing the (nonzero) coefficients
Dij for all j ∈ V and i ∈ N is manageable in a sparse format. The prostate case used 7
beam directions and the brain case used 9 beam directions. Finally, in Phase 1 of the SALO
procedure we generated a pool of |A| = 100 apertures.
2.3.2 Results and Discussion
In this section we will describe in detail how the treatment planning process based on the
SALO procedure would proceed in the two clinical cases that were solved with a radiation
oncologist present. We will illustrate the SALO procedure by going through all steps that a
treatment planner would take when developing a treatment plan. For both cases we will show
two examples of potential a priori clinical priority lists, along with a potential sequence of
decisions made by the treatment planner, for a total of four SALO applications. Furthermore,
for ease of exposition we limit ourselves in both cases to a relatively small set of criteria.
The tradeoff decisions made during the SALO process were made by a radiation oncologist.
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Table 2.1: Structures with corresponding number of voxels and gEUD-parameters for the
two clinical test cases
Site Priority Structure (s) |Vs| as γs zs zs
A B
brain 1 2 PTV 6,318 −15 0.9 63 56
2 1 chiasm 216 10 0.38 57
3 3 brainstem 1,836 10 0.5 60
4 4 optic nerve (contralateral) 218 10 0.54 63
5 5 optic nerve (ipsilateral) 247 10 0.33 63
left eye 363 63
right eye 345 63
left lens 167 63
right lens 136 63
normal tissue ring 1 6,723 62
(0–1.5 cm from PTV)
normal tissue ring 2 4,652 57
(1.5–3 cm from PTV)
normal tissue ring 3 13,037 45
(> 3 cm from PTV)
TOTAL 34,258
prostate 1 2 PTV 3,586 −5 0.3 85.5 73
2 1 rectum 8,766 8 0.4 78
3 3 bladder 5,373 2 0.85 78
4 4 penile bulb 294 1 1 85.5
5 5 femora 7,049 4 0.8 85.5
normal tissue ring 1 2,700 83
(0–1.5 cm from PTV)
normal tissue ring 2 7,203 77
(1.5–3 cm from PTV)
normal tissue ring 3 9,419 65
(> 3 cm from PTV)
TOTAL 44,390
Note that, in addition to the tradeoff curves, in our experiments the treatment planners were
also provided with summary dose distribution information for the different structures (such
as minimum, maximum, and mean dose, as well as DVH endpoints) during the process.
2.3.2.1 Brain case
For the brain case we distinguish L = 5 major gEUD criteria, one for each of the first
five structures listed in Table 2.1. We consider the two alternative priority scenarios A and
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B as indicated in that table. Figures 2.2 and 2.3 show the L − 1 stages of Phase 2 of the
SALO procedure for these two scenarios, while Figure 2.4 shows the final sets of DVH curves.
These curves show how scenario A compares to (a) LO and (b) scenario B.
Consider scenario A for the brain case in Figure 2.2. When the treatment planner begins
the process, Figure 2.2(a) is generated and presented to the planner. The treatment planner
then uses this information to assess the relationship between the gEUDs delivered to the
planning target volume (PTV) and the chiasm. In this instance, the treatment planner used
this information to choose a lower bound on the gEUD to the PTV of 53.96 Gy, as indicated
by the dot. From the graph we can then also conclude that this means that the gEUD to the
chiasm will have to be greater than or equal to 47.94 Gy. The optimization model then adds
the lower bound on the gEUD to the PTV to the set of constraints and generates Figure
2.2(b). As we can see, by slightly increasing gEUD to the chiasm it is possible to reduce
the gEUD to the brainstem by a meaningful amount. However, as we allow more dose to
the chiasm, the benefit to the brainstem lessens. Without this accurate information, the
planner would not be able to identify the clinically most beneficial tradeoff between these
two criteria. The treatment planner then follows this procedure for all other stages.
After optimizing the final criterion (i.e., minimizing the sum of all voxel doses and gen-
erating a new set of apertures given the chosen gEUD bounds) we obtain a treatment plan
whose DVHs are shown in Figure 2.4(a). In addition, the DVHs obtained by using pure LO
are shown as well. We conclude that, by accepting a minor reduction in PTV dose, all other
high priority structures receive improved dose distributions, particularly the chiasm. Our
treatment planners consider the plan generated by the SALO procedure to be superior to
the one created using pure LO. This is consistent with expectations, for if the LO plan were
more desirable, then the treatment planner would have selected the extreme points on the
tradeoff curves (representing strict prioritization). Scenario B for the brain case provides an
alternate prioritization for the criteria, and the choices made by the treatment planner are
shown in Figure 2.3. In this scenario the chiasm is of higher importance than the PTV and
is constrained before the gEUD to the PTV. Finally, Figure 2.4(b) shows that the difference
between the two scenarios is relatively small, indicating a level of robustness of the procedure
with respect to interchanging the priorities of PTV and chiasm.
2.3.2.2 Prostate case
For the prostate case we also distinguished L = 5 major gEUD criteria, again one for
each of the first five structures listed in Table 2.1. We consider the two alternative priority
scenarios A and B as indicated in that table. Figures 2.5 and 2.6 show the L − 1 stages of
Phase 2 of the SALO procedure for these two scenarios, while Figure 2.7 shows the final set
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Figure 2.2: SALO progression for the brain case, scenario A: (a) stage 1, (b) stage 2, (c)
stage 3, and (d) stage 4
of DVH curves. These curves show how scenario A compares to (a) LO and (b) scenario B.
For the prostate case, the procedure progresses in a similar fashion as for the brain case.
However, in this case most of the clinically desired treatment planning goals were more easily
satisfied. Therefore, instead of searching for a clinically feasible treatment plan, the SALO
process as applied here primarily focused on finding the most desirable treatment plan. For
scenario A the first tradeoff is presented in Figure 2.5(a). Instead of just focusing on meeting
treatment goals, the treatment planner can decide how aggressively they wish to treat the
PTV. For the next sets of tradeoffs, a similar line of reasoning is used, and Figure 2.7(a)
allows a comparison of the DVHs obtained by the SALO procedure and pure LO. As in
the brain case, a minor reduction in PTV dose allowed for significant reductions in dose to
critical structures, especially the rectum.
When selecting desired tradeoffs on the plots, it is critical to pay close attention to the
scales on the axes. For example, in Figure 2.5(c) it can be seen that small changes in the
bladder yields relatively large improvements in the femora. In contrast, in Figure 2.5(d) the
absolute differences are very small in magnitude and clinically insignificant due to the model
being very tightly constrained at that stage in the optimization.
In scenario B for the prostate case the rectum received the highest priority. In this
case, the treatment planner decided to be slightly more aggressive with respect to the PTV.
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Figure 2.3: SALO progression for the brain case, scenario B: (a) stage 1, (b) stage 2, (c)
stage 3, and (d) stage 4
As seen in Figure 2.7(b), the rectum receives more dose using the priorities in scenario B,
while the femora receives less. However, these changes are less dramatic than those between
scenario A and pure LO.
2.3.3 SALO Methodology Discussion
Through these processes, we can see how the prioritization aspect of LO has been inte-
grated with the interactive nature of MCO. By combining these two characteristics, clinically
desirable treatment plans were generated systematically and efficiently.
Without a treatment planning system with the flexibility to automate the SALO proce-
dure, this analysis would not be clinically feasible. For treatment planning systems that allow
plug-ins, implementing the SALO procedure is a straightforward process, and the clinical
benefits could be realized quite easily. That is, the procedure can be implemented without
changing a clinic’s current treatment plan solver. Programmers need only to set up some
background data structures and a coherent user interface.
The main downside to this type of implementation is that the usability heavily depends
on efficiently approximating the tradeoff curve between criteria. If the solver is too slow,
the treatment planner could be wasting time waiting for the tradeoff generation. One way
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Figure 2.4: Brain case: DVHs for treatment plan for (a) scenario A versus LO and (b)
scenario A versus scenario B
to speed up the solving process is use a solution methodology that benefits from previous
solution information. For the linear program applied to the brain and prostate cases in
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Figure 2.5: SALO progression for the prostate case, scenario A: (a) stage 1, (b) stage 2, (c)
stage 3, and (d) stage 4
Section 2.3.2, the solution algorithm used the most recent iteration’s solution to initialize
the solver for the next point on the tradeoff curve. Another way to speed up the process
is to design a solver to run on a graphics processing unit (GPU). When properly designed
and coded, models solved using GPUs allow for significant increases in speed (see, e.g., Men
et al., 2010).
In practice, it might be beneficial to supplement the SALO procedure with other dose
distribution information. Dose distribution statistics and DVHs for points along the trade-
off curves can be generated with little extra computational effort and would bolster the
information presented to treatment planners. Because all calculations up to the first stage
tradeoff assessment can be done without treatment planner interaction, different first stage
scenarios can be generated to influence decisions on the full prioritization. That is, a treat-
ment planner can first look at a few tradeoff curves before deciding the final importances of
criteria. Finally, for the treatment planners interested in the final relative weights between
the different criteria, these values can be recreated after the SALO procedure is completed
(see Breedveld et al., 2009 for this method).
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Figure 2.6: SALO progression for the prostate case, scenario B: (a) stage 1, (b) stage 2, (c)
stage 3, and (d) stage 4
2.4 SALO Extensions and Improvements
The following section is an extension of the SALO methodology developed with assistance
from two undergraduate researchers, Ruqing Ye and Christian Svetnicka. This section will
also use the FMO formulation of the IMRT treatment planning problem rather than the
DAO formulation presented earlier in the chapter. However, the technique can be extended
easily for the DAO formulation.
2.4.1 Pros and Cons of SALO
As discussed earlier, SALO has many advantages that make it more attractive over tradi-
tional multicriteria optimization techniques. The SALO procedure is more computationally
efficient than full-frontier methods of multicriteria optimization, mainly because it avoids
the complex navigation of multidimensional Pareto frontiers. In addition, SALO is flexible
in ways that lexicographic ordering methods are not. Lastly, SALO is interactive with the
clinician, allowing him/her to rank criteria and maintain control over the entire process,
rather than take a completely hands-off approach, like with lexicographic ordering.
However, SALO also has some disadvantages as well. For instance, the interactivity
that was previously listed as an advantage can be time-consuming. Clinicians are busy
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Figure 2.7: Prostate case: DVHs for treatment plan for (a) scenario A versus LO and (b)
scenario A versus scenario B
medical professionals, and many don’t have time to work with a fully interactive treatment
planning method such as SALO. Along with that point, patients often need treatment as
27
soon as possible, and the slow interactivity can delay the treatment planning. Another
disadvantage of SALO is that, while improving over multicriteria optimization, SALO is still
prone to examining clinically unacceptable or irrelevant tradeoffs, which can again waste
time. Lastly, SALO only deals with relative criteria values rather than absolute values. This
is because SALO compares criteria against each other rather than against absolute values,
which may be clinically significant. This can be problematic because certain tradeoffs may
not make sense clinically (given absolute values), but SALO will still compare them because
it is constructed to assume that there is still a relative tradeoff to be made.
2.4.2 SALO with Automation
It is not surprising that a procedure such as SALO has drawbacks. Two significant
drawbacks are the slow interactivity of the procedure and the exploration of irrelevant or
unnecessary tradeoffs. This is because these drawbacks contribute directly to wasted time.
Therefore, we would like to improve the aspects of SALO that unnecessarily lengthen the in-
teraction process. Trivial choices occur when the tradeoff calculated has no clinical relevance
or produces an immediately clear choice, and the generation of unnecessary tradeoffs occurs
when sections of the tradeoff curve are calculated that would never be considered in the final
treatment plan. We seek to automate decisions regarding obvious and/or clinically irrelevant
choices so as to improve the treatment planning process and save clinicians’ valuable time.
In order to automate this process, we obtained more information from clinicians to incor-
porate into the treatment planning model. After speaking with our collaborators, we believe
that clinicians are able to provide an upper and lower bounds on the clinically relevant
ranges of our criteria. The upper bounds would signify a “worst case” limit that we will not
allow the dose distribution to exceed. The lower bounds would signify a limit beyond which
improvements in the treatment planning criteria no long have clinical impact. That is, we
gain no benefit for improving the criteria beyond that limit. These bounds will be used to
identify a “critical region” where tradeoff selection is nontrivial.
2.4.3 SALOA Model
We propose a modification to SALO we’re calling sensitivity analysis in lexicographic
ordering with automation (SALOA) that improves upon the existing SALO methodology by
incorporating new criteria bound information from clinicians. This information includes a
lower limit, GL` , and “worst case” upper limit, G
U
` , for each criterion. Any tradeoffs that
exist outside of the range determined by GL` and G
U
` are not clinically relevant and would
not be calculated; it would be frivolous and inefficient to consider points that improve upon
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the clinical lower limit, and it would also be clinically unacceptable to consider points worse
than the worst case upper limit. Therefore, the added constraint G`(z) ≤ GU` will ensure
that unacceptable plans will not be considered. As mentioned before, we consider the FMO
formulation of the IMRT treatment planning model.
The general model is similar to SALO, but with an additional constraint to bound the
criteria by GU` , and it is described as follows:
minimize
(x,z)
{G`(z), G`+1(z)}
subject to (P
(`)
SALOA)
zj =
∑
i∈N
Dijxi for j ∈ V (2.21)
G`′(z) ≤ G`′ `′ = 1, . . . , `− 1 (2.22)
xi ≥ 0 i ∈ N (2.23)
z ∈ Z (2.24)
G`(z) ≤ GU` ` = 1, . . . , L (2.25)
where xi represents the intensity of beamlet i in set of beamlets N and Dij is the dose to
voxel j from beamlet i at unit intensity.
The interactive process differs from SALO. In the original SALO procedure, endpoints,
or points very close to the true endpoints, of the Pareto frontier are generated using an
objective function of the form αG`(z) + (1−α)G`+1(z) for different values of α, using a high
value of α to generate the endpoint (Gα` , G
α
`+1) (for which G` will be lowest and G`+1 will be
highest) and a low value of α to generate an approximate endpoint (Gα` , G
α
`+1) (for which G`
will be highest and G`+1 will be lowest), high- and low-α being almost one and almost zero,
respectively. With traditional SALO, the algorithm would then use the Sandwich Algorithm
to approximate the Pareto frontier by constructing both an upper and a lower bound on the
frontier. SALO thus produces a full or nearly full Pareto frontier for G` and G`+1. However,
this may result in calculating clinically irrelevant areas of the Pareto frontier. Instead, in
SALOA, we compare these endpoints to the values of GL` ,G
L
`+1,G
U
` and G
U
`+1. If the endpoints
are outside of the clinically relevant region, SALOA will automatically determine the next
step that should be taken based on this information.
The following rules for determining the relevant region, in which the tradeoff curve inter-
sects the critical region, help us generate a clinically relevant tradeoff curve for criteria G`
and G`+1:
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max{GL` , Gα` } ≤ G`(z) ≤ max{min{GU` , Gα` },max{GL` , Gα` }} (2.26)
Gα`+1 ≤ G`+1(z) ≤ min{GU`+1, Gα`+1}. (2.27)
Let us define the critical region as the rectangular region for which the tradeoff curve
must be displayed to the physician if the tradeoff curve overlaps with it (see Figure 2.8). It
is defined by the values in the rectangle generated by the corners (GL` , G
U
` ) and (G
L
`+1, G
U
`+1).
Additionally, the endpoint-joint line is the line that connects the two endpoints determined
by the high and low values of α/.
Figure 2.8: Critical region of clinical relevance for G1 and G2
2.4.4 Solution Methodology
First, we must determine whether there exists a tradeoff in the clinically significant
tradeoff region for our criteria G` and G`+1. If there is not a relevant tradeoff, we are
then able to automatically select a value without having to engage the planner to choose a
tradeoff. However, if there is a relevant tradeoff to be decided upon, then we must generate
the tradeoff curve for the clinically relevant values of G` and G`+1. To implement this
procedure, we examine two major scenarios, with difference in the position of the high-α
point: (I) Gα`+1 ≤ GL`+1 and (II) GL`+1 < Gα`+1 ≤ GU`+1. Each major scenario will then have
minor scenarios to consider and will be evaluated based on the constraints of the given stage.
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The first major scenario, (I), to consider occurs when the tradeoff curve never crosses the
threshold for the lower limit value of G`+1, that is, G
α
`+1 ≤ GL`+1. Three minor scenarios are
given under this major scenario:
(Ii) G
α
` ≤ GL` and Gα` ≤ GL` ,
(Iii) G
α
` ≤ GL` and GL` < Gα` ≤ GU` ,
(Iiii) G
L
` < G
α
` ≤ GU` and GL` < Gα` ≤ GU` .
These three minor scenarios can be seen in Figure 2.9. In scenario (Ii), it is notable that
the tradeoff curve never crosses the threshold for the lower criterion limit for the higher-
weighted criterion G`. In other words, for all values of α, G` will always be outside of
the clinically relevant region of tradeoffs. Hence, for scenario (i), we can choose the bound
for G` to be G
L
` , that is, G` = G
L
` . This will produce the most clinically desirable value
for G` while also maintaining significant flexibility for the remaining tradeoffs between the
subsequent criteria.
In scenario (Iii), the tradeoff curve originates in the clinically irrelevant region for G`,
but ends in the clinically relevant region for G`. In such a case, the bound for G` can again
be selected automatically as GL` . This is because all values between G
α
` and G
L
` are clinically
irrelevant and need not be considered. Then, out of the remaining possible tradeoffs, GL`
achieves the most clinically desirable value for G` while also maintaining significant flexibility
for the remaining tradeoffs between the subsequent criteria because of (I).
In scenario (Iiii), the tradeoff curve is contained entirely in the clinically relevant region
for G`. In this case, it would be logical to choose the value of G
α
` as G`. This is the value
that produces the most clinically desirable value for G` given the tradeoff curve, while still
allowing flexibility for the remaining tradeoffs between the subsequent criteria.
Upon examination of the results of each of the three minor scenarios, it can be concluded
that G` is always the maximum of G
L
` and G
α
` , when G
α
`+1 ≤ GL`+1. Therefore, G` = max
{GL` , Gα` }.
The second major scenario, (II), to consider occurs when the tradeoff curve does cross
the threshold for the lower limit of G`+1, that is, G
L
`+1 < G
α
`+1 ≤ GU`+1. Potential endpoint
locations for major scenario (II) are shown in Figure 2.10. The different black lines are
potential realizations of the tradeoff curve between the endpoints.
Two minor scenarios are given under this major scenario. For (IIi), the endpoint-joint
line potentially intersects with the critical region with Gα` ≥ GL` , and we would present to
the physician the part of the curve which is included in the critical region to choose the
upper bound G`. It should be noted that a potential arrangement of endpoints not shown
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Figure 2.9: Example endpoint locations and possible tradeoff curves for major scenario (I)
with Ii: Red Square Iii: Blue Diamond, Iiii: Green Octagon
on Figure 2.10 is that with one endpoint in the critical region and one not. The two shown
in the figure are just to show that the endpoints themselves need not be in the critical region
to be associated with this minor scenario. That that effect, the entire tradeoff curve does
not need to be presented. Rather, only the curve contained within the critical region has to
be presented to the physician. In Figure 2.11, the orange region represents the region where
the curve could potentially exist. Only curves that intersect with the yellow critical region
would be generated. Finding this intersection requires the calculation of new endpoints for
the clinically relevant tradeoff curve (i.e., intersection points with the critical region). The
new upper endpoint can be found by solving the model with the constraint G` ≥ GL` and
the new lower endpoint can be found by solving the model with the constraint G`+1 ≥ GL`+1.
The curve between the two points will then be generated and displayed to the physician for
input.
For (IIii), the endpoint-joint line does not intersect with the critical region, thus there is
no clinically relevant tradeoff to be made. The upper bound for G` can then be automatically
selected with G` = G
L
` . This is the value that achieves the best, clinically significant value for
G` while maintaining significant flexibility for the remaining tradeoffs with the subsequent
criteria.
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Figure 2.10: Example endpoint locations and possible tradeoff curves for major scenario (II)
with IIi: Red Square, IIii: Blue Diamond
Figure 2.11: Feasible region for the convex tradeoff curve for minor scenario IIi given endpoint
locations
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2.4.5 SALOA Results
As a proof of concept, we looked at a clinical protocol (L = 14) for a head and neck
case. This case used 11 beam directions. Instead of looking at the treatment plan quality of
SALO and SALOA, we instead investigated the number of times the FMO solver, the most
time-consuming subroutine, is called and the number of times physician input is required.
Due to the influence of the first criterion selection’s aggressiveness, we consider different
levels of constraining PTV coverage and see how these metrics are impacted versus SALO.
Table 2.2: Number of solver calls and physician input queries for SALO and SALOA
Technique: PTV coverage # Solver Calls # Physician Inputs
SALOA: low PTV 36 1
SALOA: med-low PTV 39 2
SALOA: med PTV 52 5
SALOA: med-high PTV 52 5
SALOA: high PTV 58 7
SALO 81 13
In Table 2.2, we see that the SALOA technique provides both fewer solver calls and fewer
physician interactions while still presenting the treatment planning with relevant tradeoffs.
2.5 Conclusions
The SALO and SALOA procedures provide treatment planners with a directed, sys-
tematic process to treatment plan selection. By following a physician’s prioritization, the
treatment planner can avoid wasting effort considering clinically inferior treatment plans.
The planner is guided by criteria importance, but given the information necessary to accu-
rately assess the tradeoff between criteria each stage. When applied to clinical cases, the
SALO procedure efficiently generated desirable treatment plans. The SALOA procedure
improved upon the computational efficiency of SALO. As treatment planning becomes more
individualized and complex with new techniques and models, methods that efficiently guide
the treatment planner towards desirable plans will be necessary to implement these advances
at the clinical level.
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CHAPTER III
Beam Orientation Optimization
3.1 Introduction
The set of machine instructions necessary for defining a treatment plan depends on the
treatment modality. In this chapter, we will focus on developing a model that integrates
two levels of machine instructions for IMRT and an associated solution methodology. IMRT
delivers radiation from a set of beam locations around the patient with the gantry stationary
during delivery. The linear accelerator is equipped with an MLC that, using sliding tungsten
leaves, dynamically produces shapes that partially block radiation (see Figure 1.2) called
apertures. From each beam location, radiation from multiple apertures at different intensities
enable a spatially complex dose distribution to be delivered within the patient. The machine
instructions to be determined are (1) the orientation of the stationary beam locations around
the patient and (2) the apertures and their corresponding intensities to be delivered at each of
these beam locations. For (1), often referred to as beam orientation optimization (BOO), we
would like a small number of stationary locations around the body (e.g., 5-9 beam locations)
that, when used as the beam set B′ in an FMO problem (see 1.2.1), produces a high quality
treatment plan. For (2), given beam set B′, we would like to find the intensity profile using
FMO followed by LS (there is potential for analogous development with DAO).
BOO can be approached in several ways: manual or pre-determined beam selection,
local searches and metaheuristics, constructive methods, and combinatorial programming.
An in-depth look into beam selection methodologies can be found in Ehrgott et al., 2008.
In clinical practice, beam selection has the potential to be an arduous, time consuming
process. The potential gains of BOO in some more accessible cancer locations (e.g., prostate
cancer) are believed by many physicians to be insignificant compared to the time investment.
Therefore, treatment planners will often use a predetermined beam arrangement (e.g., 7
equispaced coplanar beams) to determine (1). Historically, these arrangements have been
successful in allowing for clinically desirable dose distributions for the patient. In more
36
complicated cases, treatment planners will visually inspect the case and select beams that,
in their experience, seem as if they will produce a high-quality treatment plan when solving
for (2). While this method may produce quick results, the selected beams may not be
optimal or even desirable when considering all possible arrangements. The added flexibility
in allowing non-coplanar beam arrangements further exacerbates these concerns.
Most BOO literature presents algorithmic methods for determining beam locations. One
class of methods for addressing (1) determines beam orientations by iteratively searching
the set of potential beam arrangements. These can be local searches (see, e.g., Aleman
et al., 2008a; Lee et al., 2011; Craft , 2007) or metaheuristic searches (see, e.g., Bertsimas
et al., 2013; Bedford and Webb, 2006, 2007; Pugachev et al., 2000). Sometimes beam quality
evaluation metrics are considered, such as beams-eye-view (BEV), pseudo-beams-eye-view
(pBEV), and mean organ-at-risk (see Goitein et al., 1983; Pugachev and Xing , 2001; D’Souza
et al., 2004, respectively). In these methods, beams are independently evaluated and ranked
to be selected based on these criteria. Others consider a greedy framework and evaluate each
iteration’s beam selection with the knowledge of previous selected beams (see, e.g., Breedveld
et al., 2012). Lastly, some research considers integer programming formulations of (1) and
(2) (see Aleman et al., 2008b; Lim et al., 2007; Lim and Cao, 2012; Meedt et al., 2003; Miˇsic´
et al., 2010; Yarmand et al., 2013), but these often take too long to solve in a clinical setting
when considering large numbers of non-coplanar potential beam locations.
We study the problem of determining (1) while explicitly incorporating treatment plan
quality (i.e., the outputs of (2)). To this end, we integrate the BOO and FMO treatment
planning models to simultaneously decide (1) and (2). The output of this model is a set of
beam locations and the associated intensity profiles for each active location. LS will still need
to be performed in order to obtain deliverable apertures, but we assume this occurs without
incident. Section 3.2 details the BOO and FMO integrated model and our proposed solution
methodology. We apply our methodology to several clinical cases and compare the results
to existing methodologies in Section 3.4 and discuss the results and methods in Sections
3.4.2 and 3.4.3. Lastly, we present some theoretical work on objective function bounding in
Section 3.5 and give some suggestions for clinical use and future research in Section 3.6.
3.2 Treatment Planning Models
Notation for these models is consistent with that presented in 1.2.1.
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3.2.1 Traditional FMO Model
First we consider the traditional FMO model reproduced below from 1.2.1, given some
fixed beam set B′ ⊂ B and treatment planning objective function F (z). In PFMO below, the
fixed active beam set, B′, is fixed before any other machine instruction decisions are made.
PFMO is solved with decision variables x and z.
minimize
(x,z)
F (z)
subject to (PFMO)
zj =
∑
b∈B′
∑
i∈Nb
Dbijxbi j ∈ V (3.1)
xbi ≥ 0 b ∈ B′, i ∈ Nb (3.2)
3.2.2 Integrated BOO and FMO Model
For the integrated model, determining which B′ ⊂ B is a decision in the model. In BOO,
a relatively small subset B′ ⊂ B, such that |B′| << |B|, from the set of potential beam
locations is selected. The chosen set of locations must allow for a high quality treatment
plan to be delivered while being small enough to be deliverable in a clinically reasonable
amount of time. The integrated BOO and FMO treatment planning model can be set up
as follows. Let F (z) be the treatment planning objective function. Model PBOOFMO represents
the full integrated model, where the decision variables are the contents of set B′ ⊂ B and
variables x and z.
minimize
(B′,x,z)
F (z)
subject to (PBOOFMO )
zj =
∑
b∈B
∑
i∈Nb
Dbijxbi j ∈ V (3.3)
xbi ≥ 0 b ∈ B′, i ∈ Nb (3.4)
xbi = 0 b ∈ B\B′, i ∈ Nb (3.5)
We would like to solve this integrated model to produce a desirable treatment plan while
keeping |B′| small. Because treatment plan quality is dependent on patient geometry, a strict
bound on |B′| should not be imposed. Instead, the tradeoff between |B′| and treatment plan
quality is considered.
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This problem can be expressed as a subset selection problem. Let X (B′) be the set of
feasible solutions given active set B′ (i.e., X (B′) = {(x, z) : (3.3), (3.4), (3.5)}) and F(B′) be
a minimum F (z) such that (x, z) ∈ X (B′). Therefore, the updated problem, PBOOFMO , can be
written as follows keeping in mind that we want to control |B′|):
min
B′⊂B
F(B′). (3.6)
3.3 Solution Methodology for PBOOFMO
The goal of the integrated BOO and FMO model is to select beams while explicitly con-
sidering treatment plan quality in both coplanar and non-coplanar settings. However, solv-
ing this type of model to optimality can be prohibitively time consuming for large potential
beam location sets (see Yarmand et al., 2013), which occurs when considering high-resolution
coplanar and most non-coplanar beam arrangements. Using heuristic methods is a common
way of avoiding these computational pitfalls when selecting beam orientations provided that
they produce high-quality arrangements. Because of the computational advantages and po-
tentially high performance, we consider a greedy framework for subset selection. Let us
define ∆F(B′, b) as the difference between F(B′) and F(B′ ∪ {b}) for some b ∈ B\B′ with
B′ ⊂ B:
∆F(B′, b) = F(B′ ∪ {b})−F(B′). (3.7)
A greedy subset selection algorithm can now be presented in this context.
• Step 0: Set B′ = ∅
• Step 1: Find b∗ = argminb∈B\B′ ∆F(B′, b)
– If ∆F(B′, b∗) ≥ 0, stop
• Step 2: Set B′ = B′ ∪ {b∗}
– If |B′| reaches a pre-determined maximum size, stop
– If F(B′) is of desirable quality, stop
– Otherwise, go to Step 1
The output of this algorithm will be the set of beams to be delivered as well as the
associated fluence maps for delivery (i.e., (B′, x, z)). A major computational drawback to
39
this general greedy algorithm is that Step 1 in each iteratoin involves O(|B|) evaluations of
function F(B′), a large-scale optimization problem. When considering non-coplanar beam ar-
rangements where |B| is large, this is clinically undesirable. Instead, we would like to replace
the beam evaluation function, ∆F(B′, b), with some approximation function, ∆F˜(B′, b), in
Step 1 of the greedy algorithm. We also want to define ∆F˜(B′, b) such that the stopping
condition in Step 1, ∆F˜(B′, b) ≥ 0, holds if there is no benefit to adding any additional
beams.
We would like the function ∆F˜(B′, b) to accurately and efficiently predict the benefit
of adding a beam without explicitly computing ∆F(B′, b). Therefore, the remainder of the
section will focus on methods of prediction. There has been work done in this area in signal
processing. Matching pursuit (MP) is commonly used in subset selection problems (see
Mallat , 1993; Tropp et al., 2006). In MP, the algorithm greedily selects the next element of
the subset based on which element provides the best local improvement, i.e., using first-order
information. While the integrated BOO and FMO model does not exactly fit this specific
problem structure, the motivation behind these algorithms provides insight into quantifying
∆F˜(B′, b), especially the idea of iteratively looking at first-order information. In Sections
3.3.1 and 3.3.2, we develop approaches that utilize first-order information to assess the quality
of each beam. Section 3.3.3 explores using second-order information.
3.3.1 KKT Motivation
One of the methods for determining apertures and aperture intensities (decisions (2)
from Section 3.1) in the literature is DAO (see, e.g., Romeijn et al., 2005). DAO utilizes
an iterative, greedy approach to generating apertures and their associated intensities given
a particular beam arrangement, explicitly solving for decision (2). The subproblem for
quantifying aperture quality, which is evaluated for each beam, is derived from studying the
Karush–Kuhn–Tucker (KKT) conditions for the treatment planning problem formulated for
aperture optimization. KKT conditions are the necessary conditions for a solution to be
optimal that use first order information (see Boyd and Vandenberghe, 2004). The general
idea is to evaluate the KKT condition associated with beams in B\B′ and add the beam
that most violates that condition.
In order to have a single KKT condition associated with each beam, we present an
artificially extended version of PFMO. We introduce variable qb for b ∈ B and objective
function weight ηb. We show KKT multipliers pi, ρ
+, and ρ− to the right of their associated
constraints.
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minimize
(x,z,q)
F (z) +
∑
b∈B
ηbqb
subject to (PKKTFMO )
zj =
∑
b∈B
∑
i∈Nb
Dbijxbi j ∈ V (pij)
xbi ≤ qb b ∈ B; i ∈ Nb (ρbi)
xbi ≥ 0 b ∈ B; i ∈ Nb. (γbi)
qb ≥ 0 b ∈ B (ξb)
The restricted version of this problem, show below, fixes set B′ = B¯′. This is the analogous
to evaluating F(B¯′) with the addition of variable qb and objective weight ηb.
minimize
(x,z,q)
F (z) +
∑
b∈B
ηbqb
subject to (PKKTFMO (B¯′))
zj =
∑
b∈B
∑
i∈Nb
Dbijxbi j ∈ V
xbi ≤ qb b ∈ B; i ∈ Nb
xbi ≥ 0 b ∈ B¯′, i ∈ Nb
xbi = 0 b ∈ B\B¯′, i ∈ Nb
qb ≥ 0 b ∈ B
Each iteration, we solve PKKTFMO (B¯′) and check it’s corresponding solution to the KKT
conditions of PKKTFMO . The conditions read as follows:
pij = [∇F (z)]j (3.8)∑
j∈V
Dbijpij + ρbi − γbi = 0 b ∈ B; i ∈ Nb (3.9)
ηb −
∑
i∈Nb
ρbi − ξb = 0 b ∈ B (3.10)
ρbi (xbi − qb) = 0 b ∈ B; i ∈ Nb (3.11)
−γbixbi = 0 b ∈ B; i ∈ Nb (3.12)
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ξbqb = 0 b ∈ B (3.13)
ρbi, γbi ≥ 0 b ∈ B; i ∈ Nb (3.14)
ξb ≥ 0 b ∈ B. (3.15)
For our problem, we assign ηb the value of 0 for all b to make model P
KKT
FMO (B¯′) and
function F(B¯′) achieve the same optimal dose distribution. With that replacement made,
note that with a substitution, we must have the following:∑
i∈Nb
ρbi ≤ 0. (3.16)
Notice that a solution to PKKTFMO (B¯′) satisfies all conditions except the following:
pij = [∇F (z)]j (3.17)
ρbi = γbi −
∑
j∈V
Dbijpij b ∈ B; i ∈ Nb (3.18)∑
i∈Nb
ρbi ≤ 0 b ∈ B. (3.19)
These can be combined into a single constraint for each beam, including inactive beams,
through substitution and a little logic (i.e., notice that γbi ≥ 0). Let us define new notation
v¯bi, such that,
v¯bi =
(∑
j∈V
Dbij [∇F (z)]j
)−
b ∈ B, i ∈ Nb, (3.20)
with the constraint in question written as the following:∑
i∈Nb
v¯bi ≥ 0 b ∈ B. (3.21)
By plugging in the optimal solution with active beam set B′, these conditions may be
checked. If they are satisfied, then B′ is an optimal beam arrangement. If they are not, then
the beam for which the condition below has the largest violation is added. Because F(B′)
was solved to optimality with active beam set B′, the only constraints that might not be
satisfied in the optimal solution to the restricted problem are those associated with inactive
beams in B\B′. Therefore, the largest violation is found solving the following subproblem
through enumeration.
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max
b∈B\B′
∑
i∈Nb
vbi (3.22)
It should be noted that the vector v¯b = {vbi|i ∈ Nb} is precisely the projected gradient of
the objective with respect to xb for each beam. This can be seen by changing the objective to
be based on x-values instead of z in the objective function through substitution of constraint
(3.3). The expression for each beam can be rewritten as the `1-norm of subvectors of these
projected gradients. ∑
i∈Nb
v¯bi = ‖v¯b‖1 ≤ 0 b ∈ B\B′ (3.23)
Therefore, the KKT-motivated predictive measure can be defined as the following:
∆F˜KKT(B′, b) = −‖v¯b‖1 b ∈ B\B′. (3.24)
3.3.2 Steepest Descent Motivation
Another approach for selecting a beam utilizes the concept of steepest descent. Given
an active beam subset B′, the beam that provides the steepest descent direction among all
potential “directions” that only involve adding a single additional beam is selected. To make
the notation cleaner, let us first reformulate the objective function to be in terms of beamlet
intensities by substituting in dose constraint (3.3).
G(xB′) = F
(∑
b∈B′
∑
i∈Nb
Dbijxbi : j ∈ V
)> (3.25)
We can present an analogous function where a single additional beam is added to the set
of active beams. Let beam b ∈ B\B′ be the additional beam.
G(xB′ , xb) = F

∑
b′∈B′
∑
i∈N ′b
Db′ijxb′i : j ∈ V
> +(∑
i∈Nb
Dbijxbi : j ∈ V
)> (3.26)
Suppose that x¯ is an optimal solution to the integrated model using only a subset B′ ⊂ B
of the beams. This would imply that the projected gradient, [∇G(x¯B′)]−, would be zero. The
steepest descent direction allowing an additional beam b ∈ B\B′ with objective G(xB′ , xb),
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however, may be nonzero. Note that only subvector xb will be involved with the projected
gradient calculation at point (x¯B′ , 0). Therefore, the following subproblem is considered with
fixed x¯B′ .
min
xb≥0
G(x¯B′ , xb) (3.27)
The steepest descent direction, i.e., the projected gradient corresponding to the additional
beam, can be given by the following expression:
v¯b = [∇G(x¯B′ , xb)]−
∣∣
xb=0
b ∈ B. (3.28)
We then calculate the norm of this vector, ‖v¯b‖2, to get our metric of comparison for
each beam. Therefore, the steepest-descent-motivated predictive measure can be defined as
the following:
∆F˜SD(B′, b) = −‖v¯b‖2 b ∈ B\B′. (3.29)
3.3.3 Second-order Motivation
The previous two approaches both rely on the first-order rate of change in objective
function value associated with individual beamlets in candidate beams. A perhaps more
sophisticated method would use second-order information to determine a Newton-like ap-
proximation to the benefits of adding an additional beam’s flexibility to the model.
Suppose again that x¯ is an optimal solution to the restricted problem only using B′ ⊂
B. A Newton-like improving direction for G(xB′ , xb) starting from (x¯B′ , 0) may involve the
subvector xB′ , unlike the previous approaches. Therefore, for each beam b ∈ B\B′, we
consider the following subproblem.
min
xB′ ,xb≥0
G(xB′ , xb) (3.30)
The difficulty in this subproblem lies in the non-negativity constraints on the beam-
let intensities (xB′ , xb), as a projected Newton direction for this problem at (x¯B′ , 0) is not
guaranteed to be improving (see Bertsekas , 1982). Instead, beamlet indices that are not
promising candidates for change are identified, i.e., beamlets with zero intensity and strictly
positive partial derivative of the objective function. This would indicate that the improving
direction for a beamlet with these characteristics would be to decrease in intensity, which is
impossible. Let us denote the indices of all beamlets of concern that have this quality by set
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N+(xB′ , xb).
N+(xB′ , xb) =
⋃
b′∈B′∪{b}
{
(b′, i) : i ∈ Nb′ , xb′i = 0, ∂G(xB′ , xb)
∂xb′i
∣∣∣∣
x=x¯
> 0
}
(3.31)
The Newton direction, wb, at x = (xB′ , xb), is generally in the form of
wb = −M(x)∇G(x), (3.32)
whereM(x) is a positive semi-definite matrix and ∇G(x) is the gradient of G at the current
solution. Using set N+(xB′ , xb), we constructM in the following way. This is an improving
direction if one exists (see Bertsekas , 1982).
[M(x)]−1ii′ =
0, i 6= i′, and either i ∈ N+(xB′ , xb) or i′ ∈ N+(xB′ , xb)∂2G(x)
∂xi∂xi′
, otherwise
(3.33)
In order to quantify this value, we consider the Newton decrement. This value can
be related to the quantity G(x¯B′ , 0) − infxB′ ,xb Gˆ(xB′ , xb), where Gˆ(xB′ , xb) is the second
order approximation of G at (x¯B′ , 0). This value is traditionally used in the unconstrained
Newton’s method, but we consider a different interpretation to adapt it for our use. In Boyd
and Vandenberghe (2004), it is described as “the directional derivative of G at (x¯B′ , 0) in
the direction of the Newton step.” Therefore, the expression can be seen as the dot product
between the projected gradient and the direction of the newton step. The expression (3.35)
is derived from equation (3.34) using the direction w˜b. We can then define ∆F˜(B′, b) with
x¯ = (x¯B′ , 0).
λ(x¯) =
√(
[∇G(x¯)]+)>∇2G(x¯)−1∇G(x¯) (3.34)
∆F˜SO(B′, b) = −
√(
[∇Gr(x¯)]+
)>M(x¯)∇Gr(x¯) (3.35)
Numerical Issues Because the creation of set N+(x¯B′ , x¯b) involves identifying beamlet
intensities that are zero, it may be beneficial to include beamlets with intensities that are
very close to zero. Therefore, we consider -nearness when generating the set N+(x¯B′ , x¯b).
That is, we can redefine set N+(x¯B′ , x¯b) as the following equation for implementation.
N+(x¯B′ , x¯b) =
⋃
b′∈B′∪{b}
{
(b′, i) : i ∈ Nb′ , xb′i < , ∂G(xB′ , xb)
∂xb′i
∣∣∣∣
x=x¯
> 0
}
(3.36)
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3.4 Application
3.4.1 Assessing the BOO Methodology
We would like to compare our methods to clinical practice and other beam-ranking strate-
gies. To this end, we consider a coplanar equispaced strategy, BEV strategy, and pBEV
strategy as methods with which to compare. The pBEV original methodology requires a
lower PTV bound our FMO model lacks, so we modify pBEV to apply it to our FMO
model. We also consider turning on all potential beams to see how far our solutions are from
an “ideal” arrangement.
Another consideration when comparing plans is whether or not to change the objective
function when beam arrangements change. Since we do not have a consistent and fair way to
redefine objective function weights depending on beam arrangement or other factors, we keep
the same model parameters and objective weights regardless of beam arrangement. While in
practice parameter tweaking would occur once an arrangement is found, we do not consider
that step of the planning process for our comparisons. We are assessing these models in
terms of objective function value, which we assume to be a good indication of treatment
plan quality relative to other plans optimized using the same objective function.
3.4.1.1 Equispaced Beam Strategy
An equispaced strategy is an arrangement of beams that are angularly equally-spaced in
a coplanar arc around the patient. Clearly, given a desired number of active beams, there
are multiple ways to select equispaced beams. In order to avoid selecting an equispaced
arrangement that is subpar given the number of beams and resolution of beam sampling, we
solve the FMO with B′ set to each potential equispaced arrangement given our discretization
and take the best in terms of objective function value.
3.4.1.2 BEV Methodology
Goitein et al. (1983) provide a simple method for determining beam quality. This method
was described in Lee et al. (2011), which is the source we reference when implementing the
metric. For each beam, the BEV metric counts the number of PTV voxels that have a dose
coefficient above some κ > 0. The metric is as follows:
∆F˜BEV(B′, b) =
∑
s∈T
∑
j∈Vs
min
{
1,
∑
i∈Nb
rij
}
, where rij =
1, Dbij ≥ κ0, otherwise , (3.37)
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with rij as the indicator variable used in the counting process. It should be noted that this
metric does not take into account other active or inactive beam interactions or delivered
dose.
In order to select κ, we first calculated the metric with a number of values between 0
Gy and the maximum Dbij value in target voxels. We then selected κ for comparison by
selecting the κ that produced the lowest objective values when the arrangements associated
with each tested κ were solved using an FMO.
3.4.1.3 pBEV Methodology
Pugachev et al. (2000) and Pugachev and Xing (2001) present pBEV. Let Ts be the PTV
threshold value and D¯bj is the dose delivered to voxel j from beam b when considering the
model with a single beam and some “maximum” intensity profile. In order to calculate this
dose, the following steps are taken (these are reproduced here from their 2001 paper).
1. Find the voxels affected by the beamlet
2. Assign the beamlet an intensity that could deliver a dose equal to or higher than the
prescription in every target voxel
3. For each organ-at-risk (OAR) or normal tissue voxel crossed by the beamlet, calculate
the ratio by which the beamlet intensity has to be reduced to ensure that tolerance is
not exceeded
4. Find the minimum ratio from the data in step 3
5. Reduce the beamlet Intensity assigned in Step 2 accordingly to the minimum ratio.
This value represents the maximum usable intensity of the beamlet
6. Repeat steps 1-5 for all relevant beamlets to obtain the “maximum” beam intensity
profile, in which none of the beamlet intensities can be further increased without vio-
lating the tolerance of some structure
7. Perform a forward dose calculation using the “maximum” beam intensity profile
8. Compute the overall score of the chosen beam direction according to an empiric score
function as follows:
∆F˜pBEV(B′, b) =
∑
s∈T
1
|Vs|
∑
j∈Vs
(
D¯bj
Ts
)2
. (3.38)
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The difficulty in applying this approach is that we don’t have threshold values for the
OARs other than 0 Gy. Instead, we propose that we solve an FMO problem for each beam
and then use the resulting dose distribution for D¯bj. Then, high quality beams should have
higher values when evaluated with equation (3.38).
3.4.2 BOO Results
These cases were run using a C++ implementation of the pricing problem along with
a custom graphical processing unit (GPU) FMO solver for the restricted master problem
(RMP). Eigen basic linear algebra subprograms (BLAS) was used for the linear algebra
subroutines on the CPU pricing problem. Some of these cases are available for optimizers
in Craft et al. (2014). We considered a piece-wise quadratic voxel-based objective function
(see Romeijn et al., 2004). Let tj be the target dose value for each voxel and αj and βj be
the over- and under-dosing penalties, respectively.
F (z) =
∑
j∈V
αj
(
(zj − tj)+
)2
+
∑
j∈V
βj
(
(tj − zj)+
)2
(3.39)
First, we want to examine if our metrics do a good job in estimating ∆F(B′, b). Let
us consider the situation where we’ve added a few beams to the model and are considering
adding an additional beam. In Figures 3.1 and 3.2, let the “Explicit” line be the outright
calculation of ∆F(B′, b), i.e., the optimal value of FMO for each potential beam. We present
a first-order method and the second-order method estimations scaled using linear regression.
We do this to show the relative differences in metrics across different beams for each metric.
The asterisks represents the beam which would be chosen for each method. The beams are
sorted by angular position around a coplanar axis. In Figure 3.1, 2 beams have already been
selected. We see the second-order “Hess” methodology selects the beam physically closest
to the “best.” It should be noted that the “best” beam in the long run is not necessarily
the one selected using explicit calculation of ∆F(B′, b); that methodology is still heuristic in
nature. In Figure 3.2, similar predictive ability can be seen with 4 beams already added for a
prostate case. The large “humps” in the curve can be seen at places where beams are already
delivering radiation, and thus would be poor candidates when adding beams to the model.
This figure also includes the BEV and pBEV metrics. Since BEV and pBEV do not take
beam interaction into account, their predictive abilities are quite poor. The non-coplanar
results display similar prediction characteristics, but make for difficult-to-read plots and are
not shown here.
Next, we investigate if we see similar improvements in objective function value when using
our methods to the explicit methodology. We are also interested in the number of beams
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Figure 3.1: Predictive results for steepest descent and second-order methodologies scaled to
explicit ∆F(B′, b) calculation for |B′| = 2 on a coplanar head-and-neck case case
needed to achieve the same quality as a coplanar arrangement. In Figure 3.3, we see that
for an equispaced coplanar arrangement on a prostate case with 60 beams, we can achieve
the objective of the best 5-beam equispaced plan with 4 beams using our methods. We also
see that our methodologies cause decreases in the objective function almost identically to
explicitly calculating ∆F(B′, b). In Figure 3.4, a brain case, we look at the coplanar and
non-coplanar versions of our methods. The non-coplanar arrangements get close to achieving
the same objective as turning on all 60 coplanar beams. In this brain case, 394 non-coplanar
beams are considered. Figure 3.5 compares our methods on a non-coplanar liver case with
56 beams. We outperform BEV and pBEV significantly.
Clinically, we are also interested in how using non-coplanar beam changes how dose is
distributed in the body. Consider Figures 3.6 and 3.7. Figure 3.6 shows a dosewash of the
patient treated with 7 equispaced beams and Figure 3.7 shows the same patient treated with
7 potentially non-coplanar beams selected using the second-order method. The redistribution
of can be seen in a reduction in the normal tissue. Non-coplanar directions allow for the dose
to spread out a little more around the patient. Another way of visualizing dose to a patient
is in a dose-volume histogram (DVH). A DVH shows the fractional volume of a structure
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Figure 3.2: Predictive results for steepest descent and second-order methodologies scaled to
explicit ∆F(B′, b) calculation for |B′| = 4 on a coplanar prostate case case
Figure 3.3: Objective function value vs. added number of beams for a coplanar prostate
case with 60 beams
(y-axis) that receives some dose or higher(x-axis). The goal is to have a uniform high dose
to the cancerous tissue, while delivering lower doses to organs at risk. On the DVH, this
means that we want a step function that starts at 100% then steps down to 0% at the desired
target dose and for the organs at risk to have curves that are near to the bottom left corner.
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Figure 3.4: Objective function value vs. added number of beams for a brain case with 60
coplanar beams and 394 non-coplanar beams
Figure 3.5: Objective function value vs. added number of beams for a liver case with 56
non-coplanar beams
In the DVH in Figure 3.8, we see the 7-beam second-order plan (dashed) dominates the
7-beam equispaced plan almost everywhere. We observed this behavior in all non-coplanar
arrangements with our methodology versus equispaced coplanar arrangements.
3.4.3 Methodology Discussion
For each of these methods, we see good performance that is better than what many are
doing in the clinic. However, are these methodologies viable in a clinical environment? There
are other considerations to take into account before answering this question.
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Figure 3.6: Dosewash of 7 equispaced beams
Figure 3.7: Dosewash of 7 beams selected using the second order method
First, we assume a fixed objective function. In reality, this will be adjusted to the
physician’s and treatment planner’s goals. New objective functions would call for a rerun
of the integrated model, i.e., generate new beams, with the current framework. While
the solution methodology might allow for that, generating a new beam arrangement can
(dramatically) change the set of feasible dose distributions for the treatment plan. This
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Figure 3.8: DVH for the patient from Figures 3.6 and 3.7
can lead to inefficient tweaking and too much guesswork involved in changing the objective
function each iteration. Instead, it might be better to use some kind of pre-planning objective
function weight estimation technique (see, e.g., Chan et al., 2014) to define the objective used
to determine a beam arrangement, then tweak the plan with that fixed arrangement as is
traditionally done.
Second, there is the issue of computational efficiency. Clinically, the act of finding beams
needs to be fast enough not to hinder the treatment planner’s workflow. Consider the run
times presented in Figure 3.9. We can see the computation time for the different methods.
The KKT methodology and the first-order method have essentially the same computational
footprint at about one second per iteration, so only one is shown (“Grad”). The second-
order (“Hess”) and explicit methodology take much longer. Considering the performance of
the first-order methods, we recommend that they be used clinically over the second-order
methodology. It should be noted that this was implemented by a non-professional coder,
but with efficient libraries. We believe these numbers are proportionately reflective of a
high quality CPU implementation. However, these run times could be further improved
with a cloud- or GPU-implementation of the pricing problem provided the large amount of
coordinated data can be efficiently handled.
Finally, the greedy nature of the algorithm could be a problem. While we believe that
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Figure 3.9: Computation time for calculating beam score, |B| = 60
the inherent flexibility of beam selection problem (i.e., different “pretty good” arrangements
will do almost as well as the optimal arrangement) will allow our methods to perform well,
we did consider ways to control or reduce the impact from the greedy beam selection. First,
we considered adding and removing beams. However, when we did some numerical exper-
iments with this, dropping and adding new beams didn’t have a significant enough impact
to merit further pursuits. We also considered post-processing heuristics, but others (e.g.,
Aleman et al., 2008a) have studied neighborhood searches and other beam angle adjustment
algorithms. Our methodology could produce a seed arrangement for these post-processing
heuristics.
This last point about post processing led us to question how close we were to an optimal
arrangement and if there were bounds we could derive to gather this information. While
numerical results have not been generated on these bounds, the theoretical groundwork is
presented in Section 3.5.
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3.5 Bounding on the Optimal Objective Value
An aspect of this problem to consider is how we might bound the optimal objective value,
both on F(B′) and F(B). We would like to assess the quality of our methodology against
bounds in addition to the empirical case results presented earlier. We would also like to use
these bounds to gain insight into the problem and inspire future work to be done on this
topic. This section presents a series of proofs that lay the groundwork for bounding both
the FMO and DAO versions of the integrated problem.
3.5.1 Bounding F(B) Using an FMO Model
First, our optimal objective value given a restriction on the number of active beams, B¯,
can be seen as the following:
min
B′⊂B,|B′|≤B¯
F(B′). (3.40)
Clearly, for |B¯′| < |B¯′′|, we have the following relationship:
min
B′⊂B,|B′|≤B¯′
F(B′) ≥ min
B′′⊂B,|B′′|≤B¯′′
F(B′′). (3.41)
Therefore, a lower bound on the objective function value for any stage can be found
evaluating F(B), i.e., allowing all beams. This value is the ideal plan objective that we
would like to approach with a small subset of the beams. By comparing our solutions to this
value, we can assess how close we get to a bound on the optimal solution.
However, evaluation of F(B) involves solving a |B|-beam FMO, which may be compu-
tationally undesirable or even infeasible. In the non-coplanar setting, the sizes of the |B|
dose-to-point matrices prohibit explicit evaluation on our memory-constrained in-house GPU
solver. While a custom CPU solver was developed for this purpose, the custom CPU solver
still cannot handle more than around 300 beams (around 24GB of dose-to-point matrices
stored in binary format). For larger beam sets, there are methods of approximating bounds
on F(B).
3.5.1.1 Bounding F(B) given a feasible solution
In order to develop a bound on F(B), we assume that beamlet intensities are not allowed
to go above some upper limit, mbi, for each beam b ∈ B and beamlet i ∈ Nb.
Consider an optimization problem of the following form:
minimize
(x,z)
F (z)
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subject to (P¯UB)
zj =
∑
b∈B
∑
i∈Nb
Dbijxbi j ∈ V (3.42)
xbi ≥ 0 b ∈ B, i ∈ Nb (3.43)
xbi ≤ mbi b ∈ B, i ∈ Nb. (3.44)
The solution to this problem represents the “best” dose distribution possible given all
beams can be modulated. Since we often cannot solve this problem due to the size of |B|,
we would like to develop a bound on the optimal solution. Let x = {xbi : b ∈ B, i ∈ Nb},
z = {zj : j ∈ V}, and D = [D1 . . . D|B|] and let G(x) = F (Dx).
Lemma III.1. Let F (z) be a convex function. Then G(x) = F (Dx) is a convex function.
Proof. dom G = {x : Dx ∈ dom F}. Therefore, the affine mapping preserves convexity, so
G is convex (see Boyd and Vandenberghe, 2004, Section 3.2.2).
Using this knowledge, we can rewrite the problem in terms of x only for simplicity in
notation.
minimize
x
G(x)
subject to (G¯UB)
xbi ≥ 0 b ∈ B, i ∈ Nb
xbi ≤ mbi b ∈ B, i ∈ Nb
Our next goal is to find a bound on the optimal value to the above problem using a
feasible, but not optimal, solution. Let ∇G(x) be the gradient of G(x) and x ∈ XUB
represent x satisfying the constraints of G¯UB.
Theorem III.2. Let x¯ ∈ XUB and x∗ = argminx∈XUB G(x). Then,
G(x¯) +∇G(x¯)>τ ≤ G(x∗) (3.45)
with τ ∈ R|N | such that
τbi =
mbi − x¯bi if [∇G(x¯)]bi < 0−x¯bi if [∇G(x¯)]bi ≥ 0 ∀b ∈ B, i ∈ Nb. (3.46)
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Proof. By convexity of the function G we have the following relationship:
G(x¯) +∇G(x¯)>(x∗ − x¯) ≤ G(x∗). (3.47)
Let [∇G(x)]bi be term {bi} of the gradient of G(x). Observe that we can calculate the
largest improvement a change in particular variable can contribute to the objective. Every
term [∇G(x¯)]bi(x∗bi − x¯bi) is bounded below by the following:
[∇G(x¯)]bi(x∗bi − x¯bi) ≥
[∇G(x¯)]bi(mbi − x¯bi) if [∇G(x¯)]bi < 0[∇G(x¯)]bi(−x¯bi) if [∇G(x¯)]bi ≥ 0 ∀b ∈ B, i ∈ Nb. (3.48)
With τ defined as above, we have the relationship:
∇G(x¯)>τ ≤ ∇G(x¯)>(x∗ − x¯), (3.49)
which when combined with previous statements shows that our initial claim holds.
G(x¯) +∇G(x¯)>τ ≤ G(x¯) +∇G(x¯)>(x∗ − x¯) ≤ G(x∗) (3.50)
Now that we have an expression for a bound, we would like to know if the information
necessary can be calculated and the bound evaluated.
G(x¯) =
∑
j∈V
αj
((∑
b∈B
∑
i∈Nb
Dbijx¯bi − tj
)+)2
+
∑
j∈V
βj
((
tj −
∑
b∈B
∑
i∈Nb
Dbijx¯bi
)+)2
(3.51)
[∇G(x¯)]bi = 2
∑
j∈V
αjDbij
(∑
b′∈B
∑
i′∈Nb
Db′i′jx¯b′i′ − tj
)+
− 2
∑
j∈V
βjDbij
(
tj −
∑
b′∈B
∑
i′∈Nb
Db′i′jx¯b′i′
)+
(3.52)
Here αj and βj are the over-dosing and under-dosing penalties, respectively. tj is the
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threshold parameter. The relevant dimensions of the data are in the D matrix and in the
parameters of the function G. For the FMO representation of the machine instructions, xbi
represents beamlet intensity, D ∈ R|N |×|V|. Using the quadratic objective below, the other
data exists in R|V|. These sizes lend themselves to manageable calculation sizes and therefore
the bound can be computed easily given any x¯ ∈ XUB.
3.5.1.2 Bounding F(B) given an optimal solution using a fixed subset of beams,
B′
Another piece of information we’re interested in is a bound on the optimal objective
function using only a subset of the beams, |B′| << B. Consider the following BOO and
FMO integrated formulation.
minimize
(B′,x,z)
F (z)
subject to (P¯BOOFMO )
zj =
∑
b∈B
∑
i∈Nb
Dbijxbi j ∈ V
xbi ≥ 0 b ∈ B′, i ∈ Nb
xbi ≤ mbi b ∈ B′, i ∈ Nb
xbi = 0 b ∈ B\B′, i ∈ Nb
|B′| ≤ B¯ (3.53)
Theorem III.3. Let B′′ be some arrangement B′′ ⊂ B with |B′′| = B¯ with optimal solution
x∗B′′ (i.e., solving P¯
BOO
FMO with B′ = B′′). Suppose that we have an arrangement Bˆ such that
Bˆ ⊂ B′′ and |Bˆ| < B¯. Let x¯Bˆ be a feasible vector for P¯BOOFMO . Then,
G(x¯Bˆ) +∇G(x¯Bˆ)>φ ≤ G(x∗B′′), (3.54)
with ‖φ‖0 = B¯ calculated as
[φB′′ ]bi =

mbi − [x¯Bˆ]bi if [∇G(x¯Bˆ)]bi < 0, b ∈ B′′
−[x¯Bˆ]bi if [∇G(x¯Bˆ)]bi ≥ 0, b ∈ B′′
0 if , b ∈ B\B′′.
(3.55)
Proof. By convexity we have the following relationship:
G(x¯Bˆ) +∇G(x¯Bˆ)>(x∗B′′ − x¯Bˆ) ≤ G(x∗B′′). (3.56)
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Note that each term [x∗B′′ ]bi = x¯Bˆ = 0 for all b ∈ B\B′′, i ∈ Nb. Therefore, ‖(x∗B′′−x¯Bˆ)‖0 ≤
B¯ for any potential arrangement B′′. By observing the maximum change in decision variables,
each term [∇G(x¯Bˆ)]bi[(x∗B′′ − x¯Bˆ)]bi is bounded below as follows:
[∇G(x¯Bˆ)]bi[(x∗B′′ − x¯Bˆ)]bi ≥

[∇G(x¯Bˆ)]bi(mbi − [x¯Bˆ]bi) if [∇G(x¯Bˆ)]bi < 0, b ∈ B′′
[∇G(x¯Bˆ)]bi(−[x¯Bˆ]bi) if [∇G(x¯Bˆ)]bi ≥ 0, b ∈ B′′
0 if , b ∈ B\B′′.
(3.57)
With φ defined as above, the following relationship then holds:
G(x¯Bˆ) +∇G(x¯Bˆ)>φB′′ ≤ G(x∗B′′). (3.58)
We can extend this to apply to an optimal beam arrangement given that Bˆ beams are
included in the arrangement. Let B∗(Bˆ) signify an optimal arrangement given Bˆ ⊂ B∗. We
have:
min
B′′⊂B
G(x¯Bˆ) +∇G(x¯Bˆ)>φB′′ ≤ G(x∗B∗(Bˆ)). (3.59)
Let φ = φB′′ , such that,
B′′ = argmin
B′′⊂B
G(x¯Bˆ) +∇G(x¯Bˆ)>φB′′ . (3.60)
We can easily find the corresponding φ by greedily selecting the smallest B¯ − |Bˆ| terms
of [∇G(x¯Bˆ)]bi[φ]bi as each term is independent of subset selection B′′.
3.5.2 Bounding F(B) Using a DAO Model
Another method of determining a dose distribution given a fixed beam set to consider is
DAO using potential beam locations as potential aperture locations. Column generation is
the standard method of solving DAO, allowing us to avoid the previously mentioned memory
issues of solving F(B). The resulting objective function value will be an approximation to
F(B) if the column generation process is halted before all potentially beneficial columns
are added. Generating 1000+ apertures can provide some insight into an “ideal” solution.
However, this is still an approximation, and we would like to develop theoretical bounds on
the objective function value. We consider a way to make the FMO presented earlier with
upper bounds on the beamlet intensities equivalent to a DAO-like procedure, then use that
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equivalence to develop new bounds on the optimal solution of F(B). Let us consider the
DAO pricing problem with a beam-on-time bound.
3.5.2.1 DAO Pricing Problem with Beam-On-Time Bound
Let µb be the upper bound on total beam intensity, and let Kb be the set of deliverable
apertures for beam b. Let ybk be the intensity of aperture k on beam b. The following is the
DAO Master Problem:
minimize
(y)
H(y)
subject to (H¯BB)
ybk ≥ 0 b ∈ B, k ∈ Kb (3.61)∑
k∈Kb
ybk ≤ µb b ∈ B. (3.62)
Let γb be the dual variable associated with the beam-on-time constraint and ρbk be the
dual variable associated with the non-negativity constraint. As before, the dose deposition
constraint is contained in the objective function. Then, in addition to primal feasibility, the
KKT conditions for this master problem would be the following:
γb ≥ 0 b ∈ B (3.63)
ρbk ≥ 0 b ∈ B, k ∈ Kb (3.64)
γb(
∑
k∈Kb
ybk − µb) = 0 b ∈ B (3.65)
−ybkρbk = 0 b ∈ B, k ∈ Kb (3.66)
[∇H(y)]bk − ρbk + γb = 0 b ∈ B, k ∈ Kb. (3.67)
Now consider formulation H¯DAOBB that only allows certain apertures K′b ⊂ Kb to have
positive intensity. Let y ∈ YDAOBB represent a feasible solution for H¯DAOBB . This is the form of
the DAO RMP:
minimize
(y)
H(y)
subject to (H¯DAOBB )
ybk ≥ 0 b ∈ B, k ∈ Kb
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∑
k∈Kb
ybk ≤ µb b ∈ B
ybk = 0 b ∈ B, k ∈ Kb\K′b.
After obtaining optimal solution y∗ ∈ YDAOBB to H¯DAOBB , we want to check if it violates any
of the KKT conditions for the original master problem. First consider the KKT conditions
to the DAO RMP below:
γb ≥ 0 b ∈ B
ρbk ≥ 0 b ∈ B, k ∈ Kb
γb(
∑
k∈Kb
y∗bk − µb) = 0 b ∈ B
−y∗bkρbk = 0 b ∈ B, k ∈ Kb
[∇H(y∗)]bk − ρbk + γb = 0 b ∈ B, k ∈ Kb.
Without loss of generality, we can assume that y∗bk > 0 for k ∈ K′b, b ∈ B. This can be
easily realized by noticing that we can solve the model for some K′b, remove any zero-intensity
apertures from K′b, and then resolve to obtain the same solution with all apertures having
positive intensities. This means that for every k ∈ K′b and b ∈ B, we have ρbk = 0. For any
beam b using the entire allowed intensity amount µb (i.e., allowing non-negative γb), we can
calculate γb = −[∇H(y∗)]bk for any k ∈ K′b.
The conditions that the optimal solution to the RMP could potentially violate in the
master problem are constraints (3.64) and (3.67). These can be summarized as the following:
ρbk ≥ 0 b ∈ B, k ∈ Kb
[∇H(y)]bk + γb = ρbk b ∈ B, k ∈ Kb.
Therefore, we need to have the following condition satisfied.
[∇H(y)]bk + γb ≥ 0 b ∈ B, k ∈ Kb (3.68)
Then, for each beam b ∈ B, we would like to find the following:
min
k∈Kb
[∇H(y)]bk + γb. (3.69)
Note: γb = 0 for all beams that are not using all of their allowed µb intensity. Otherwise,
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we use γb calculated as above.
This can be easily altered address the beam-on-time constraint in Theorem III.5.
3.5.2.2 Bounding F(B) Given an Optimal Solution Using a Subset of Apertures
Let y ∈ YBB represent a feasible solution to problem H¯BB and let y ∈ YDAOBB represent a
feasible solution for H¯DAOBB .
Theorem III.4. Let y¯ = argminy∈YDAOBB H(y) and y
∗ = argminy∈YBB H(y). Then,
H(y¯) +
∑
b∈B
µb min
k∈Kb\K′b
[∇H(y¯)]bk ≤ H(y∗). (3.70)
Proof. Clearly, y¯ ∈ YBB. By convexity,
H(y¯) +∇H(y¯)>(y∗ − y¯) ≤ H(y∗). (3.71)
Now consider [∇H(y¯)]bk(y∗bk − y¯bk) for k ∈ K′b, b ∈ B. Since no improving direction exists
for problem H¯DAOBB in those dimensions, we have
0 ≤
∑
b∈B
∑
k∈K′b
[∇H(y¯)]bk(y∗bk − y¯bk). (3.72)
Thus, we only need to consider [∇H(y¯)]bk(y∗bk − y¯bk) for k ∈ Kb\K′b, b ∈ B. Note that for
each beam b, the total change in aperture dose is bounded above by µb by constraint (3.62)
due to y¯ ∈ YDAOBB . Therefore, the following bound holds for each beam.
µb min
k∈Kb\K′b
[∇H(y¯)]bk ≤
∑
k∈Kb\K′b
[∇H(y¯)]bk(y∗bk − y¯bk) ∀b ∈ B. (3.73)
We then have a bound on H(y∗).
H(y¯) +
∑
b∈B
µb min
k∈Kb\K′b
[∇H(y¯)]bk ≤ H(y∗) (3.74)
In order to calculate this bound, we need to be able to find mink∈Kb\K′b [∇H(y¯)]bk for each
beam b ∈ B. The traditional DAO pricing problem finds mink∈Kb [∇H(y¯)]bk and does not
consider constraint (3.62). However, there is an updated pricing problem that incorporates
constraint (3.62) (see Section 3.5.2.1).
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This can be extended to problems with constraint (3.62) replaced by an overall beam-
on-time constraint. Consider the following optimization model.
minimize
(y)
H(y)
subject to (H¯DAOOB )
ybk ≥ 0 b ∈ B, k ∈ Kb∑
b∈B
∑
k∈Kb
ybk ≤ T
ybk = 0 b ∈ B, k ∈ Kb\K′b
Theorem III.5. Let y¯ = argminy∈YDAOOB H(y) and y
∗ = argminy∈YOB H(y). Then,
H(y¯) + T min
k∈Kb,b∈B
[∇H(y¯)]bk ≤ H(y∗). (3.75)
Proof. Clearly, this can be seen as all apertures having a single “beam” bound. Given this
observation, this proof structure is identical to that in Theorem III.4.
3.5.2.3 Bounding F(B) Given a Feasible Solution Considering All Potential
Apertures
We would like to consider y¯ to be any feasible solution to H¯OB below. This would mean
that it is possible for all of the |K| apertures to have non-negative values.
minimize
(y)
H(y)
subject to (H¯OB)
ybk ≥ 0 b ∈ B, k ∈ Kb∑
b∈B
∑
k∈Kb
ybk ≤ T (3.76)
Let the feasible region here be define as YOB.
Theorem III.6. Let y¯ ∈ YOB and y∗ = argminy∈YOB H(y). Then,
H(y¯) + T min
k∈Kb
b∈B
y¯bk<T
[∇H(y¯)]bk − T max
k∈Kb
b∈B
y¯bk>0
[∇H(y¯)]bk ≤ H(y∗). (3.77)
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Proof. Clearly, we have:
H(y¯) +∇H(y¯)>(y∗ − y¯) ≤ H(y∗). (3.78)
For each k ∈ Kb, b ∈ B we have:
[∇H(y¯)]bk(y∗bk − y¯bk) ≥
[∇H(y¯)]bk(T ) if [∇H(y¯)]bk < 0[∇H(y¯)]bk(−T ) if [∇H(y¯)]bk ≥ 0 ∀b ∈ B, k ∈ K′b. (3.79)
Because of constraint (3.76), we know that the total increase and total decrease in intensity
are each bounded by T . That is,
‖(y∗ − y¯)+‖1 ≤ T (3.80)
and
‖(y¯ − y∗)+‖1 ≤ T. (3.81)
Therefore, we have the following bounds:
T min
k∈Kb
b∈B
y¯bk<T
[∇H(y¯)]bk ≤
∑
b∈B
∑
k∈Kb
y¯bk<T
([∇H(y¯)]bk)− (y∗bk − y¯bk)+ (3.82)
and
− T max
k∈Kb
b∈B
y¯bk>0
[∇H(y¯)]bk ≤ −
∑
b∈B
∑
k∈Kb
y¯bk>0
([∇H(y¯)]bk)+ (y¯bk − y∗bk)+. (3.83)
Combining our previous statements, we have satisfy our theorem.
H(y¯) + T min
k∈Kb
b∈B
y¯bk<T
[∇H(y¯)]bk − T max
k∈Kb
b∈B
y¯bk>0
[∇H(y¯)]bk ≤ H(y∗) (3.84)
This may be difficult to calculate for the general case due to the calculation involving all
potential apertures that could potentially occur.
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3.5.2.4 Bounding F(B) Given a Feasible Solution Using a Subset of Apertures
Consider problem H¯OB and RMP H¯
DAO
OB . We let y¯ be any feasible solution to H¯
DAO
OB and
then use that to calculate a bound on the optimal solution of H¯DAOOB .
minimize
(y)
H(y)
subject to (H¯DAOOB )
ybk ≥ 0 b ∈ B, k ∈ Kb∑
b∈B
∑
k∈Kb
ybk ≤ T
ybk = 0 b ∈ B, k ∈ Kb\K′b
Theorem III.7. Let y¯ ∈ YDAOOB and y∗ = argminy∈YDAOOB H(y). Then,
H(y¯) + T min
k∈Kb\K′b,b∈B
[∇H(y¯)]bk + T min
k∈K′b
b∈B
y¯bk<T
[∇H(y¯)]bk − T max
k∈K′b
b∈B
y¯bk>0
[∇H(y¯)]bk ≤ H(y∗) (3.85)
Proof. By Theorem III.4, we have the following relationship:
T min
k∈Kb\K′b,b∈B
[∇H(y¯)]bk ≤
∑
b∈B
∑
k∈Kb\K′b
[∇H(y¯)]bk(y∗bk − y¯bk). (3.86)
Now we must find a lower bound for the following:∑
b∈B
∑
k∈K′b
[∇H(y¯)]bk(y∗bk − y¯bk). (3.87)
Note that these variables are in the structure as Theorem III.6. Therefore, we apply
Theorem III.6 to get the following bound on H(y∗).
H(y¯) + T min
k∈Kb\K′b,b∈B
[∇H(y¯)]bk + T min
k∈K′b
b∈B
y¯bk<T
[∇H(y¯)]bk − T max
k∈K′b
b∈B
y¯bk>0
[∇H(y¯)]bk ≤ H(y∗) (3.88)
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3.5.3 Equivalence of Pricing Problem Constraints
Consider the bounded FMO model from Section 3.5.1.1 and the bounded DAO model
from Section 3.5.2.2. The main difference is between constraints (3.44) in the FMO model
and (3.62) in the DAO model. The physical differences in apertures and individual beamlets
(i.e., deliverability requirements) contribute to this modeling discrepancy. The reason we
consider these two models is that we want a bound on the BOO/FMO integrated model
using a DAO bounding technique. In order to have the bound be relevant, we must have the
FMO feasible region be contained in the DAO feasible region. Ideally, the regions would be
equivalent.
xbi ≤ mbi b ∈ B, i ∈ Nb (3.44)
and∑
k∈Kb
ybk ≤ µb b ∈ B (3.62)
Let us assume that µb = mbi for all b ∈ B and i ∈ Nb. First, we consider if (3.62) implies
(3.44). That is, if we have a feasible solution to the DAO model using constraint (3.62),
can we guaranty a feasible solution to the FMO model with constraint (3.44) with the same
objective function. We do so by finding beamlets that produce the same dose distribution.
Lemma III.8. Let y¯ ∈ YDAOBB . Then, ∃ x¯ ∈ XUB such that z = Dx = Dy.
Proof. Let
x¯bi =
∑
k∈Kb
s.t. i∈Nk
y¯bk b ∈ B, i ∈ Nb. (3.89)
Then, by our our definition of z = Dx and z = Dy, we have z = Dx¯ = Dy¯. x¯ satisfies
the non-negativity constraints. We see that the total dose any x¯bi is assigned is less than µb,
and thus constraint (3.44) holds.
Next, we consider if (3.44) implies (3.62). That is, if we have a feasible solution to the
FMO model with constraint (3.44), can we guaranty a feasible solution to the DAO model
using constraint (3.62) with the same objective function. We do so by finding apertures that
produce the same dose distribution.
Unfortunately, this does not necessarily work. We can see using a simple example. Let
us consider a single beam with a single row of three beamlets with intensities (µb,0,µb). We
can see that there is not any deliverable aperture shape to satisfy this intensity mapping.
Therefore more than µb intensity is necessary to deliver that map.
66
However, if we relax the MLC constraints on the DAO problem (i.e., allow undeliverable
apertures to exist in Kb), then we can deliver any beamlet intensity map with at most µb
total aperture dose for each beam. Let K˜b be the set of all potential apertures (disregarding
deliverability) for beam b ∈ B. Let Y˜DAOBB be the associated feasible region with Kb replaced
by K˜b.
Theorem III.9. x¯ ∈ XUB ⇐⇒ y¯ ∈ Y˜DAOBB such that Dx¯ = Dy¯.
Proof. First, it follows from Lemma III.8 that if y ∈ Y˜DAOBB , then we can find x¯ ∈ XUB such
that Dx¯ = Dy¯ because YDAOBB ⊆ Y˜DAOBB .
Second, we would like to show that if x¯ ∈ XUB, then ∃ y¯ ∈ Y˜DAOBB such that Dx¯ =
Dy¯. Since deliverability is no longer a concern, we use the following procedure to generate
apertures and assign intensities.
• Step 1: Generate aperture k′ ∈ K˜b consisting of beamlet set Nk′ such that i ∈ Nk′ if
x¯bi > 0
• Step 2: Set y¯bk′ = min{x¯bi : i ∈ Nk′}
• Step 3: Set x¯bi = x¯bi − y¯bk′ for all i ∈ Nk′
• Step 4: If any x¯bi > 0, then go to Step 1. Otherwise, end.
We can see that by constructing the aperture intensities in this manner, we have at
most |Nb| iterations and thus at most |Nb| apertures. Each iteration, at least one beamlet
will drop out from the set of beamlets with positive intensity. Because we are reducing all
non-zero beamlet intensities uniformly, the highest total aperture dose we can have is the
maximum beamlet intensity, µb. Therefore, constraint (3.62) holds. With all other non-
generated apertures zero, the non-negativity constraints hold. Lastly, by our definition of
z = Dx and z = Dy, we have z = Dx¯ = Dy¯. Thus, our theorem holds.
It may be computationally beneficial to consider bounding the FMO model using the
DAO model allowing undeliverable apertures with constraints (3.44) in the FMO model and
(3.62) in the DAO model. The idea is that the fewer elements we use to undershoot the
bound, the better the bound will be. The number of apertures used in a clinically desirable
solution is traditionally fewer than the total number of beamlets.
3.5.4 Considerations and Potential Bounding Uses
While the current section has some methods for bounding F(B) and F(B′), there are some
additional considerations to account for before finding numerical results. First, coherent
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choices for mbi and µb need to be determined. What these should be is not clear as they
don’t bound these explicitly and/or consistently clinically. Also, how these bounds should
be incorporated into the algorithm’s stopping criteria is still an open question. Lastly, the
piecewise quadratic objectives used in our application may be ill-natured for these types of
bounds. Voxels far away from the threshold, tj, can produce high-valued gradients, which
can, in turn, generate grossly loose bounds. Linear objectives might provide a tighter bound,
but that has not yet been investigated
However, we believe that there are interesting uses for the theoretical work in Section
3.5, especially in an integrated BOO and DAO model. In each iteration of generating an
aperture, the model will assess whether or not to add an aperture to an existing beam
location or add an additional beam location. These types of bounding, which we believe will
be more effective in the aperture model due to the number of apertures being less than the
number of beamlets, can be integrated into the beam selection and stopping conditions of
this type of model.
3.6 Clinical Applicability and Future Research
3.6.1 Potential Clinical Implementation
Clinically, our integrated BOO and FMO model can be added into a treatment planning
system. The major downside is that the data required for the integrated model are the Dbij
values for each beam, which can be slow to calculate and expensive to store. There are
several ways to utilize the methods while sidestepping this issue.
One way to use this methodology is to use the integrated BOO and FMO model only
for the beam selection aspects of treatment planning and not for the end-of-planning FMO.
This would mean that the beam locations chosen by the integrated model, B′, would be the
fixed beam set used by treatment planners and physicians to tweak before delivery. The
presented methodology, in this respect, could be automated. It could also use downsampled
data. We did not investigate the effects of downsampling, but believe that this methodology
would continue to perform well with lower resolution voxels.
Another useful way to utilize the greedy framework is in considering when to add an
additional beam. Consider a treatment in the midst of the planning process with 8 active
beams that is unable to achieve a clinically acceptable dose distribution. Adding an addi-
tional beam will add flexibility to the model. The developed methodology can be used to
select the next beam to add to the model, even though the beam selection algorithm might
not have been used for the first 8. Estimates of the potential benefits of adding the additional
beam can also be observed.
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Lastly, this work was developed when also working on FusionArc (see Matuszak et al.,
2013), a hybrid delivery method that combines the continuous arc-based delivery of VMAT
with the stationary delivery of IMRT. A modified BOO-like algorithm was used to determine
where along an existing VMAT arc the gantry should stop and deliver an IMRT beam.
3.6.2 Future Work
Much of the groundwork for the BOO and DAO integrated model has been developed,
and we hope to study this model in the future. This type of constructive methodology is
also relevant to methods where beam locations of importance are iteratively selected (e.g.,
coplanar VMAT, FusionArc, Non-coplanar VMAT), which will be thematically evident in
chapter IV.
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CHAPTER IV
Non-coplanar Volumetric Modulated Arc Therapy
4.1 Introduction
The dose distribution a patient receives is dependent upon the machine constraints of
the delivery modality. Beams are fitted with an MLC, a device that, using sliding tungsten
leaves, can cast the beam’s output into shapes called apertures. The combination of aperture
modulation, dose rate, and beam orientation and/or movement define the different methods
of radiation delivery. Recall that there are several different treatment modalities that are
commonly used in modern radiation therapy: IMRT and VMAT. Both of these techniques
utilize a beam of radiation that is mounted on a moveable gantry that can rotate about
the body. With the ability to move the device to which the patient is fixed, called the
couch, non-coplanar beam directions can be achieved. In VMAT, the beam moves along
a coplanar arc (i.e., fixed couch position with a moving gantry) while delivering radiation
through actively changing apertures. The decisions that define a VMAT treatment plan are
the coplanar arc path, the movements of the MLC along the arc, and the dynamic dose
rate of the beam. When making these decisions, we must consider machine constraints such
as MLC leaf movement restrictions, dose rate limits, gantry speed constraints, and gantry
acceleration bounds. VMAT treatment planning is currently a hot topic among optimizers
studying treatment planning due to the difficult nature of the problem and the lack of a
standard treatment planning method (see, e.g., Peng et al., 2012; Craft et al., 2012; Papp
and Unkelbach, 2014; Unkelbach et al., 2015).
Coplanar VMAT takes advantage of the majority of the capabilities of the treatment
machine and thus is seen as one of the most state-of-the-art treatment modalities. However,
as treatment machines become more versatile in gantry and couch movement, the assump-
tion that VMAT arcs must be coplanar can be relaxed. Nearly all current VMAT modeling
techniques assume a pre-determined coplanar arc as an input to the inverse optimization for
the other decisions. We would like to consider a treatment modality where gantry and couch
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movement, dose rate, and MLC leaf movement are all dynamic without the coplanar restric-
tion applied to the beam’s arc. That is, determining the non-coplanar path of the arc through
the 4-pi space around the patient would be combined with the previously mentioned VMAT
modeling restrictions (i.e., integrating a routing problem with an already-difficult treatment
planning problem). This creates a mathematically challenging problem where solving to op-
timality is clinically infeasible. At a workshop at Massachusetts General Hospital where the
top researchers in VMAT treatment plan optimization discussed the top methodologies and
considered the future of VMAT, non-coplanar VMAT emerged as one of the most promising
next-steps for cutting-edge algorithm research. An overview of modern optimization algo-
rithms for VMAT can be found in Unkelbach et al. (2015). Other modalities may approach
delivery angles in a more flexible manner, such as a robotic arm, but these modalities are
not nearly as widespread.
4.2 Treatment Planning Models
The VMAT optimization model requires us to introduce new notation and a few new
delivery concepts. We first look at the coplanar VMAT treatment planning model, then
study the non-coplanar counterpart.
In coplanar VMAT, the beam arc is predefined and modeled as a series of ordered control
points. The set of decisions to make are the MLC leaf positions modeled as apertures at each
control point, the dose rate through each control point, and the gantry speed through each
control point. The gantry speed can also be looked at as the time spent traveling between
control points and will be referred to as such for the remainder of the chapter. MLC leaf
movement constraints must also be applied to allow adequate time between control points
for MLC leaves to shift. Lastly, we assume that the gantry and couch can accelerate and
decelerate instantaneously. This is not a realistic assumption when dealing with the standard
delivery machinery. It should be noted that the delivery machines used for IMRT are also
used for VMAT. However, this assumption is more realistic for flexible delivery modalities
like the CyberKnife M6 FIM System. In the future work of the project, we would like to
incorporate acceleration/deceleration constraints in the model, but for our study they are
omitted.
The notation in this chapter follows that presented in Section 1.2.2 with a few additions.
In VMAT, the path of the beam is often modeled as passing through a series of locations
around the patient called control points. Let K be the set of all control points and let k` be
the `th control point along the arc. For decision variables, let Ak` be the aperture delivered
at k`, rk` be the dose rate at k`, tk` be the time spent per degree traveling through control
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point k` (i.e., inverse of the gantry speed), and yk` be the intensity per degree at control
point k`. Let m be the total number of control points in the delivery arc.
For parameters, let RUk` be the upper bound on dose rate for control point k` in dose per
time, TLk` and T
U
k`
be the lower and upper bounds, respectively, on time per degree at each
control point k`, δk` be the distance in degrees at control point k`, and Dk`j(Ak`) be dose
received by voxel j ∈ V from aperture Ak` at unit intensity. Lastly, let TLk`,k`+1(Ak` , Ak`+1)
be minimum time the gantry can take traveling from k` to k`+1 and still allow for the MLC
leaf changes necessary to change from Ak` to Ak`+1 between control points k` and k`+1.
4.2.1 Traditional VMAT Model
With the above definitions, we present the traditional VMAT model with a fixed path,
(COP-VMAT-FP). In the clinical, this uses a coplanar arc.
(COP-VMAT-FP) minimize
(A,y,t,r,z)
F (z) (4.1)
subject to zj =
m∑
`=1
Dk`j(Ak`)δk`yk` j ∈ V (4.2)
yk` = rk`tk` ` = 1, . . . ,m (4.3)
δk`tk` ∈ [TLk` , TUk` ] ` = 1, . . . ,m (4.4)
rk` ∈ [0, RUk` ] ` = 1, . . . ,m (4.5)
tk` ≥ TLk`,k`+1(Ak` , Ak`+1) ` = 1, . . . ,m (4.6)
Ak` ∈ A ` = 1, . . . ,m (4.7)
Constraint (4.2) relates aperture shape and angular fluence rate to dose received. Con-
straint (4.3) combines time per degree at a control point and dose rate to create fluence.
Constraints (4.4) and (4.5) bound variables t and r. Constraint (4.7) ensures apertures
are deliverable and constraint (4.6) controls the leaf movement restrictions based on gantry
movement and adjacent apertures.
4.2.2 Non-coplanar VMAT Full Problem
We extend the traditional VMAT model by relaxing the assumptions that the arc is
predetermined and that the arc is restricted to a coplanar path. Because of these relaxations,
k` is now a decision variable representing the `
th control point in the arc. Let K be the set of
all potential control points in the 4pi space around the patient. In order to construct a path,
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we add a constraint to the model requiring k`+1 to be adjacent to k`. Let Kk` be the set
of control points adjacent to k`, with adjacency defined as being within one unit of angular
discretization in parameter space.
We present the overall non-coplanar (NCP) VMAT full problem (FP) below. We would
like to select a subset of the control points that form a path to minimize some function of the
dose while adhering to deliverability constraints. While this formulation of the model may
be unsolvable in a realistic amount of time, it may help when finding a heuristic solution.
(FP) minimize
k,A,y,t,r,z
F (z) (4.8)
subject to zj =
m∑
`=1
Dk`j(Ak`)δk`yk` j ∈ V (4.9)
yk` = rk`tk` ` = 1, . . . ,m (4.10)
δk`tk` ∈ [TLk` , TUk` ] ` = 1, . . . ,m (4.11)
rk` ∈ [0, RUk` ] ` = 1, . . . ,m (4.12)
tk` ≥ TLk`,k`+1(Ak` , Ak`+1) ` = 1, . . . ,m (4.13)
Ak` ∈ A ` = 1, . . . ,m (4.14)
k`+1 ∈ Kk` ` = 1, . . . ,m (4.15)
As stated earlier, k` represents the lth control point along the beam path, with the
path of the gantry passing through exactly m control points. Constraint (4.9) represents
the dose delivered to voxel j from apertures at active control points k1 to km. Constraint
(4.10) calculates the aperture intensity at control point k`. Constraints (4.11) and (4.12)
apply upper and lower bounds on absolute (non-directional) gantry travel time and dose rate,
respectively. Constraint (4.13) ensures sufficient gantry travel time to maintain deliverability
of adjacent apertures Ak` and Ak`+1 . Function T
L
k`,k`+1
(Ak` , Ak`+1) represents the minimum
time the gantry can take traveling from k` to k`+1 and still allow for the MLC leaf changes
necessary to change from Ak` to Ak`+1 between control points k` and k`+1. Constraint (4.14)
ensures apertures are deliverable shapes. Constraint (4.15) requires adjacent apertures in
the path. Dummy apertures are added to the beginning and end of the path ` = 0,m + 1.
These dummy apertures have no MLC movement restrictions or dose rate and serve only as
placeholders for the pricing problem.
Using a representation of travel time (rather than speed) will help us out later when
constructing a feasible solution. Travel time can be converted back to speed after the model
has been solved. For simplicity, we assume that the same speed restrictions apply to gantry
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and couch movement, but separate speed restricts can be applied to the gantry and couch
in an extension of our model.
4.2.3 Master Problem
Solving the FP outright is computationally intractable, so we investigate ways to simplify
the solution process. We start by assuming the beam travels at its slowest speed to remove
a decision from the model. A post-processing step can be performed to raise speed as much
as possible given a feasible solution. The travel time is fixed to the control-point maximum
(i.e., movement speed to the control-point minimum), TUk` (see Section 2.1 in Peng et al.,
2012 for the speed-centered version of this model). The resulting upper bound on fluence
rate of aperture yk` is δk`R
U
k`
TUk` , which we denote with Y
U
k`
. We get the following Master
Problem (MP). A feasible solution to this problem implies a feasible solution to the FP.
(MP) minimize
k,A,y,z
F (z)
subject to zj =
m∑
`=1
Dk`j(Ak`)δk`yk` j ∈ V
yk` ∈ [0, Y Uk` ] ` = 1, . . . ,m (4.16)
δk`T
U
k`
≥ TLk`,k`+1(Ak` , Ak`+1) ` = 1, . . . ,m (4.17)
Ak` ∈ A ` = 1, . . . ,m
k`+1 ∈ Kk` ` = 1, . . . ,m
4.3 Heuristic Methodology for NCP VMAT
What we would like to do with our methodology is to generate a feasible, high-quality
solution to the FP. Based on the success of the column-generation framework developed in
Peng et al., 2012, we consider a similar framework for this problem. The general idea is
to start with all k` control point locations unassigned and yk` = 0. Setting these decision
variables forms a RMP (see Section 4.3.1). We then solve the RMP to generate a deliverable,
but incomplete, treatment plan. Iteratively, we attempt to improve the current plan by
generating an aperture at an inactive control point that guarantees that we will have a feasible
solution when the algorithm terminates. That is, when m control points and apertures have
been assigned, the solution is feasible for (MP) with a connected path of control points
with apertures that are deliverable and reachable given the gantry travel time. The process
by which we select a beneficial aperture is the pricing problem (PP), and the PP will be
discussed in Section 4.3.2. After adding an aperture to the RMP, we solve the updated RMP.
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The solution to the RMP feeds into the next iteration’s PP. We continue this procedure
until m apertures are added.
4.3.1 Restricted Master Problem
Let us define the RMP given some control point set K′ ⊂ K. In RMP(K′), we fix a set
of |K′| = m′ < m control points k` ∈ K′ for ` = 1, . . . ,m′ and their associated apertures,
A¯k` . The following program solves for the associated aperture intensities with fixed control
points and aperture shapes.
(RMP(K′)) minimize
y,z
F (z)
subject to zj =
m′∑
`=1
Dk`j(A¯k`)δk`yk` j ∈ V
yk` ∈ [0, Y Uk` ] ` = 1, . . . ,m′
This program is an optimization problem with linear constraints, and thus it is a convex
optimization problem if F is a convex function. Using convex solvers, we can efficiently solve
this problem for manageable m′.
4.3.2 Pricing Problem
The overall idea for the PP is to select a control point and aperture that provide the
largest immediate benefit to the model while maintaining feasibility of MP (i.e. satisfies
constraints (4.14), (4.15), and (4.17)).
Suppose an aperture Ak¯ is inserted between control points k` and k`+1. Let us define
pik¯k`,k`+1(Ak¯) as the rate of improvement in the objective function with the addition of this
aperture based on first-order optimality conditions. Ak¯ ∈ Ak¯k`,k`+1 , where Ak¯k`,k`+1 ⊆ A is
the set of deliverable apertures that can feasibly be added at control point k¯ to the plan
given preceding aperture Ak` and succeeding aperture Ak`+1 at control points kl and k`+1,
respectively. This value can be calculated as in equation (4.18) given optimal solution (y¯, z¯)
to RMP(K′).
pik¯k`,k`+1(Ak¯) =
∑
j∈V
[−∇F (z¯)(z¯)]j Dk¯j(Ak¯)δk¯ (4.18)
Our strategy is to select a control point k¯ and aperture Ak¯ to fit in the path between
preceding aperture k` and succeeding aperture k`+1. Let P (k`, k`+1) be the set of potential
control points to consider between existing control points k` and k`+1 (see Section 4.3.2.1 for
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more detail). PP can be broadly described as below in equation (4.19).
(PP) max
`=0,...,m′
max
k¯∈P (k`,k`+1)
max
Ak¯∈Ak¯k`,k`+1
pik¯k`,k`+1(Ak¯) (4.19)
At the ends, a search is done between the end control point and some dummy control point
that has no MLC leaf restriction. Section 4.3.2.1 goes into defining the search neighborhood
P (k`, k`+1). Section 4.3.2.2 details the formulation and effect of Ak¯k`,k`+1 . Section 4.3.3
describes the PP solution procedure. Lastly, Section 4.3.3.1 discusses tie-breaking strategies.
4.3.2.1 Determining P (k`, k`+1)
P (k`, k`+1) is the control point search space between given control points k` and k`+1.
The overall idea in specifyingP (k`, k`+1) is to do two things: (i) ensure that there are always
enough remaining control points to complete the m-length path and (ii) restrict the search
space in between existing path control points to hedge against being overly greedy.
First, we consider (i). Since control points k` and k`+1) may not be adjacent, the gantry
would need to travel through a certain number of intermediate control points to reach k`+1)
from k` . Let E(k`, k`+1) be the number of control points necessary to travel between control
points k` and k`+1) along a minimum-time path (defined below) consisting of adjacent control
points. (If k` and k`+1) are adjacent, then E(k`, k`+1) = 0.)
Suppose K′ , with |K′| = m′ has been specified at the current step of the constructive
algorithm. Let J(K′) be the number of “not immediately necessary” control points, i.e.,
control points that are not “used up” to connect points in K′ with a sequence of adjacent
control points. We can compute J(K′) as the following:
J(K′) = m−m′ −
m′−1∑
`=1
E(k`, k`+1). (4.20)
Given this metric and aperture set k` ∈ K′ for ` = 1, . . . ,m′, we can make the following
claims:
• The longest feasible path between two control points k` and k`+1 is bounded by
E(k`, k`+1) + J(K′).
• The longest feasible path beyond an endpoint of the path is bounded by J(K′).
Next, we must incorporate (ii) to restrict our search space in between path control points.
One method of doing this is to consider the ratio in travel time between the path `→ k¯ →
`+1 and the path `→ `+1. Let us define Tt(k`, k`+1) as the shortest time it takes the beam
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to travel from k` to k`+1 given fixed angular travel time t and control points k` and k`+1.
Then, let T be some upper bound on this ratio. We would like to consider control points k¯
that satisfy the following ratio condition.
Tt(k`, k¯) + Tt(k¯, k`+1)
Tt(k`, k`+1)
≤ T (4.21)
We define our set of control points to consider, P (k`, k`+1), given a t, k` and k`+1.
P (k`, k`+1) =
{
k¯ :
Tt(k`, k¯) + Tt(k¯, k`+1)
Tt(k`, k`+1)
≤ T ,E(k`, k¯) + E(k¯, k`+1) ≤ J(K′) + 1
}
(4.22)
In order to calculate function Tt, let us make some additional assumptions. Assume that
the set of potential control point locations is equally spaced in parameter space in a grid
of gantry and couch orientations. We assume this for the proof-of-concept nature of the
project, but this assumption can be relaxed with updated Tt formulas. We can calculate this
time metric given an assumption on beam movement.
Let g and c be the number of control points apart k` and k`+1 are on the gantry axis
and couch axis, respectively. For example, see Figure 4.1. Let δ be the number of degrees
in spacing at each control point. Lastly, let us assume that the couch and gantry can move
simultaneously. We use a path heuristic in which the beam travels along a diagonal until it
can move in a parameter-space-orthogonal path to the destination.
Tt(k`, k`+1) = min(g, c)δt+ (max(g, c)−min(g, c))δt (4.23)
With these assumptions, calculating this expressing reduces to finding the max between
g and c.
One questions that still remains is how to deal with the endpoints of the path. Clearly,
we cannot extend past the endpoints further than J(K′) control points. However, we may
want to further restrict the search space from the endpoints. A simple bound, Eend, only
considering points within min(J(K′), Eend) control points from the endpoint may be all that
is necessary. This bound will affect how the algorithm grows the path. We could also look
at the time, Tt, to the control points past the end and restrict the search using that value.
Lastly, it may be logical to consider adding a condition that the beam cannot go back on
itself sharply from the endpoints to promote path movement around the body. While we do
not add this bound, a more in depth study of how the algorithm behaves will need to be
done before any definitive “endpoint rules” can be finalized.
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Figure 4.1: Illustration of g = 2 and c = 1 values between two red control points
4.3.2.2 Determining Ak¯k`,k`+1 and Its Implications
We need to specify set Ak¯k`,k`+1 , which is our aperture search space, in a particular way to
satisfy constraint 4.17 in MP. This constraint says that MLC leaves must be able to feasibly
move in the time between control points k`, k¯, and k`+1. Note that k¯ need not be adjacent
to the other two.
Ak¯k`,k`+1 ⊆ {A ∈ A : δk`TUk` ≥ TLk`,k¯(Ak` , A), δk`TUk¯ ≥ TLk¯,k`+1(A,Ak`+1)} ≡ Ak¯Uk`,k`+1 (4.24)
How we choose Ak¯k`,k`+1 will define the MLC capabilities at some control point k¯. As we
can see in equation (4.24), the definition of Ak¯k`,k`+1 is dependent upon the preceding and
following apertures and the upper bound on the time spent at the control point. With the
preceding and following apertures fixed, our concern is with the upper bound on the time
spent between control points. Keeping the time at the machine upper bound could allow
for a larger Ak¯k`,k`+1 , i.e., a larger search space for deliverable apertures, but may reduce the
flexibility of the model in future iterations.
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One thing to note is that the choice ofAk¯k`,k`+1 will influence the behavior of the algorithm,
especially in later stages. If we choose a smaller set Ak¯k`,k`+1 , that will result in less flexibility
in the current set of apertures, but may allow for greater flexibility in later stages. We could
consider a family of potential choices for Ak¯k`,k`+1 (see Appendix A). However, let us continue
with our assumption of a fixed travel time. This information will be used when determining
the potential MLC leaf arrangements when solving the pricing problem.
Lastly, we want to know explicitly how our selected max angular travel time, TU
k¯
, and
preceding and following apertures Ak` and Ak`+1 control the feasible aperture region. That
is, for each row, we would like to determine the feasible MLC leaf positions given TU
k¯
, k`,
and k`+1 for potential control point k¯.
Let us assume that TU
k¯
, k`, and k`+1 are fixed along with apertures Ak` , and Ak`+1 . Let
Ak¯r be the set of feasible rows for the rth row of control point k¯ of aperture Ak¯.
Ak¯r =
{
a : TUk¯ δk` ≥ TLk`,k¯(Ak`r, Ak¯r), TUk¯ δk¯ ≥ TLk¯,k`+1(Ak¯r, Ak`+1r)
}
(4.25)
Let v be the maximum speed an MLC leaf can move and N be the rightmost leaf setting.
The total distance a leaf can cover is v times the time it is moving. We can see the following
relationship.{
a : TUk¯ δk` ≥ TLk`,k¯(Ak`r, Ak¯r)
}
= {(L,R) : 0 ≤ L ≤ R ≤ N ;
|L− Lk` |, |R−Rk`| ≤ vTt(k`, k¯)
}
, (4.26)
and we can define the leaf positions as the following:
Ak¯r = {(L,R) : 0 ≤ L ≤ R ≤ N ; |L− Lk` |, |R−Rk` | ≤ vTt(k`, k¯);
|L− Lk`+1|, |R−Rk`+1 | ≤ vTt(k¯, k`+1)}. (4.27)
4.3.3 Solving the PP
Recall the pricing problem from equation (4.19).
(PP) max
`=0,...,m′
max
k¯∈P (k`,k`+1)
max
Ak¯∈Ak¯k`,k`+1
pik¯k`,k`+1(Ak¯)
For each `, k¯, we want to solve the following:
(PP(`, k¯)) max
Ak¯∈Ak¯k`,k`+1
pik¯k`,k`+1(Ak¯). (4.28)
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For a given ` and k¯, we can calculate (4.28) in the following manner for a beam with M
rows (see Peng et al., 2012).
max
Ak¯∈Ak¯k`,k`+1
pik¯k`,k`+1(Ak¯) =
M∑
r=1
max
(L,R)∈Ak¯r
R∫
L
pik¯k`,k`+1(x)dx (4.29)
We integrate across the leaf positions in order to allow fractional (i.e., non-discrete) leaf
positions. Details can be found in Peng et al. (2012), Section 2.6.1.
The overall pricing problem becomes the following problem, over which we can enumerate
due to the fact that leaf positions can only be at integer points or the leaf limit.
(PP) max
`=0,...,m′
max
k¯∈P (k`,k`+1)
M∑
r=1
max
(L,R)∈Ak¯r
R∫
L
pik¯k`,k`+1(x)dx (4.30)
We represent aperture dose in the same manner as in Peng et al. (2012), and thus will not
be described in detail here. In short, the continuous row of beamlet positions is discretized
into N beamlets. Dose is the summation of the open beamlets plus the fraction of the
partially-blocked beamlets at the locations occupied by the MLC leaves. The function we
are integrating over is a step function.
4.3.3.1 Breaking Ties in the PP
It may be possible that, for a particular control point k¯, the pricing problem produces
the same (PP(`, k¯)) values for different `. In this situation, we need rules to determine where
to insert control point k¯ and associated aperture in the path. The list below shows some
methods of how to break ties in order of execution. In our implementation, we go by the
pricing problem score (4.30), then the lowest ratio (i), then the most central (iii).
i Insert the control point where the Tt(k`,k¯)+Tt(k¯,k`+1)
Tt(k`,k`+1)
ratio is the smallest
ii Insert the control point such that Tt(k`, k¯) + Tt(k¯, k`+1) is the smallest
iii Insert the control point so that it is most central (i.e., Tt(k`,k¯)
Tt(k¯,k`+1)
is closest to 1)
iv Insert the control point into the path with the smallest ` (to definitively break all ties)
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4.4 Application
4.4.1 Brain Case Details
This model was applied to a brain case as a proof-of-concept. The data is from common
optimization for radiation therapy (CORT) dataset in Craft et al. (2014). Potential control
point set, K, consists of control points spaced 10 degrees apart along both the gantry and
couch axes totaling 648 control points. Each control point contains 160 beamlets, and the
patient was discretized into 481,915 voxels. The prescription dose for the case is 60 Gy.
The dose-to-points data were generated in the open source Computational Environment for
Radiotherapy Research (CERR) (see Deasy et al., 2003).
This case was chosen primarily for the availability of data. For this type of algorithm,
dose-to-points matrices, D, must be generated for each potential control point. While this
may be avoided in a clinical implementation of this algorithm with additional path re-
strictions, considering the full K is necessary in the presented form of the algorithm. The
algorithm was implemented in C++ using Gurobi (see Bixby et al., 2010) to solve the RMP.
4.4.2 Model Assumptions
Several assumptions were made for this initial implementation. P (k`, k`+1), the set of
control points to search between k` and k`+1, has an additional restriction of not allowing
more than E¯ control points between k`, selected point c, and k`+1. We also restricted the
search at the endpoints of the path to at most E¯end control points. The values we tested can
be seen in Table 4.1. We found that E¯ was too influential and opted for finding a value in
future test. P (k`, k`+1) was constructed in the following way:
P (k`, k`+1) =
{
k¯ :
Tt(k`, k¯) + Tt(k¯, k`+1)
Tt(k`, k`+1)
≤ T ,
E(k`, k¯) + E(k¯, k`+1) ≤ min
(
J(K′), E¯)+ 1} . (4.31)
A number of assumptions were made on how the gantry and couch move. As mentioned
before, these assumptions may not hold with conventional IMRT delivery systems, but are
more realistic for some other systems, e.g., CyberKnife M6 FIM Systems. We assume that the
beam can feasibly deliver from all 4pi angles. Ideally, we want to restrict the path to only visit
feasible control points (i.e., avoid collisions between the gantry and the couch/patient), and
that change fits within our framework. However, the collision information was not available
at the time of this project. We assume that the gantry and couch move in equispaced
parameter space at the same speed. This speed is not decoupled in the current formulation
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Table 4.1: Parameters tested over for the initial set of runs
m E¯end E T
36 4 4 2.5
36 4 8 2.5
36 4 100 2.5
36 4 100 3.5
36 8 4 2.5
36 8 8 2.5
36 8 100 2.5
36 8 100 3.5
36 10 100 2.5
36 10 100 4
of the model. Further studies must be done to determine these changes.
We assume that the couch and gantry can move simultaneously. Movement is assumed
to begin and end instantaneously (i.e., perfect acceleration/deceleration). We also assume
that the beam has no upper fluence bound.
The leaf movement speed upper bound is 4.5 cm per second and the gantry and couch
speed upper bound is 6 degrees per second. The parameters E¯end, E, and T were tested
to get ballpark estimates of what good values of these should be. A single parameter set,
bolded in Table 4.1 showing those tested, was used for the runs in the results section.
4.4.3 Results
With this proof-of-concept, we will examine treatment plan quality through dose-volume
histograms (DVHs, see 3.4.2 for DVH details) and dosewashes. These metrics are commonly
used for clinical assessment of the quality of treatment plans.
First, consider a 36 control point solution. We are interested in how well our algorithm
preforms compared with the state-of-the-art coplanar VMAT algorithm presented in Peng
et al. (2012). In Figure 4.2, we see the DVH comparing the 36 control point NCP VMAT
(solid) solution to the 36 control point coplanar VMAT (dashed) solution. The NCP VMAT
solution dominates the coplanar VMAT solution almost everywhere. This shows us that
considering non-coplanar directions for VMAT treatment can potentially yield higher-quality
treatment plans than using only the traditional coplanar arcs. However, only using 36 control
points heavily restricts our ability to take advantage of the flexibility of VMAT treatment
plant (i.e., dynamically adjusting the MLC leaf positions over the arc). We can see in Figure
4.3 that we fail to get close to the “ideal” IMRT solution that uses 36 non-coplanar control
points discovered by the NCP VMAT algorithm as beam directions. Therefore, we ask the
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question “Can we do better?”
Figure 4.2: 36 control point NCP VMAT (solid) vs. coplanar VMAT (dashed)
Figure 4.3: 36 control point NCP VMAT (dashed) vs. IMRT (solid)
To improve our solution, we interpolate along the 36-point NCP VMAT path and add
in four additional, equispaced control points in between the control points on the arc and
four more on the end to get up to 180 control points. This is a finer discretization than we
initially planned. An example of this can be seen in Figure 4.4. We then reoptimize the
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treatment plan (i.e., determine aperture shapes and aperture intensities) using the algorithm
in Peng et al. (2012) (again, without gantry acceleration/deceleration constraints) along a
predetermined non-coplanar arc.
Figure 4.4: Illustration of potential control points (blue), 36-point NCP VMAT trajectory
(red), and interpolated 180-point NCP VMAT trajectory (green)
The DVH showing this comparison can be seen in Figure 4.5. We see that a large
improvement is made by allowing greater control over the MLC leaves. We are also interested
in how far from an ideal plan this solution is. Consider optimizing an IMRT plan along the
same 180 control points. The DVH for this solution and the 180 control point NCP VMAT
along the 36-point NCP VMAT path can be seen in Figure 4.6. The 180 control point NCP
VMAT is much closer to the ideal solution than the 36 control point NCP VMAT is to the
36 control point IMRT solution.
Lastly, we would like to compare our 180 control point NCP VMAT taken from ex-
trapolating the 36 control point NCP VMAT path to a 180 control point coplanar VMAT
treatment plan. These results can be seen in the DVH in Figure 4.7. While the improve-
ments are not as significant as when considering 36 control point plans, the NCP VMAT
plan dominates the coplanar VMAT plan nearly everywhere. It should also be noted that
many of the parameter effects of the NCP VMAT model have not been studied, and the NCP
VMAT solutions presented here should not be considered to be the “best” the technique can
offer. The effects of allowing non-coplanar beam directions in VMAT treatment are more
evident when considering dosewashes. In Figure 4.8, we can see how some of the dose in
hotspots (areas of high dose in undesirable areas) is lowered by using NCP VMAT.
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Figure 4.5: 180 control point VMAT along 36 control point NCP VMAT path (solid) vs. 36
control point NCP VMAT (dashed)
Figure 4.6: 180 control point VMAT along 36 control point NCP VMAT path (dashed) vs.
180 control point IMRT (solid)
4.5 Conclusions and Future Work
Preliminary results suggest that superior treatments can be obtained without significant
increase in treatment time when using non-coplanar beams, but more extensive testing is
needed. Acceleration and deceleration constraints, as they pertain to specific VMAT delivery
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Figure 4.7: 180 control point VMAT along 36 control point NCP VMAT path (solid) vs. 180
control point coplanar VMAT (dashed)
modalities, should be implemented in the model. Gantry and couch speeds should also be
decoupled, although the gantry/couch parameter space may not be the ideal way of describing
beam location for other delivery modalities like the CyberKnife M6 FIM System.
On the clinical side, more cases should be tested with this planning framework. A full,
2-degree control point spacing should be optimized to see the effects of the algorithm on a
high-resolution search space. However, the method of interpolating between control points
on paths found using a course resolution is probably more clinically feasible. Fewer dose-to-
points matrices would need to be generated and the solution time for the algorithm would
be significantly faster. Lastly, a study in treatment time versus treatment plan quality could
be done using this type of algorithm for non-coplanar VMAT treatment plans.
A final thought for future work is in using NCP VMAT to improve existing plans or partial
plans. An incomplete path of control points can be be used as a seed for this algorithmic
framework provided they control points can be connect in the end. A treatment planner
might identify a few “high priority” locations they want the beam to pass through, and the
NCP VMAT algorithm could figure out the connecting path and associated apertures along
the path. Techniques like BOO (see III) could also be used to identify these “high priority”
control points. This is an exciting research area, and we hope to further study NCP VMAT
models in the future.
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Figure 4.8: (top) 180 control point coplanar VMAT dosewash, (bottom) 180 control point
VMAT along 36 control point NCP VMAT path dosewash
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CHAPTER V
Adaptive Treatment Planning for Lung Cancer
5.1 Introduction
When planning a radiation therapy treatment, known patient information is used to
generate a desirable treatment plan. Geometric information along with other pre-treatment
characteristics influence the resulting plan. Over the course of treatment, these patient
characteristics may change, and the planner’s initial understanding of patient information
may evolve, causing inaccuracies in the original planning model. Due to these inaccuracies,
the pre-treatment plan is often adapted to the new data by replanning and reoptimizing the
treatment plan. By incorporating the anticipation and knowledge of future changes into the
pre-treatment planning model, or “future-proofing” the treatment plan, planners may have
greater control of patient outcomes and improve the effectiveness of the treatment.
5.1.1 Adaptation Motivation
In traditional radiation therapy treatment planning, the general practice is to develop a
treatment plan and use that plan for the course of treatment. This plan is delivered over
n daily fractions, where fluence x
n
(and thus dose z
n
) is delivered in each fraction. This
has several advantages. First, it is an established method and straightforward in practice.
Second, it puts a relatively small strain on treatment planning resources (i.e., planner time,
computation time, physician time, etc.). However, not all patient information is known a
priori. The information describing a patient changes over the course of treatment, both
geometrically and physiologically. Treatments are often adapted (i.e., replanned given the
already delivered dose) when significant new information is realized.
Without considering adaptation when plans are initially generated pre-treatment, the
dose distribution already delivered at the time of adaptation may force the adapted treatment
to be inflexible in the amount it can adapt to the new information and still stay within the
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treatment planning protocol. Therefore, more sophisticated methods of adaptive planning
are sometimes considered (see Ding et al., 2007; Wu et al., 2008; Nishi et al., 2013; Hurkmans
et al., 2012; de la Zerda et al., 2007 for examples of adaptive treatment planning).
There are several reasons in addition to raising treatment quality that adaptation-conscious
planning should be considered. With treatment planning, imaging, and biomarker analysis
getting faster and more efficient (see Breedveld et al., 2012; Men et al., 2010; Long et al.,
2012, etc.), there are additional resources freed up for replanning. Dosemetrists are also
starting to plan with replanning in mind because they are realizing that considering future-
proofing initial plans can improve treatment. The quality of the treatment plan improves as
information is effectively incorporated into the model.
5.2 Lung Cancer Setting
In this chapter, we discuss possible modeling approaches to adaptive treatment planning
in radiation oncology. To make our discussion concrete, we use a specific cancer site (lung
cancer) and a specific form of new information (a particular biomarker which, as indicated
by preliminary studies, has the potential to be a good predictor of the likelihood of a certain
radiation side effect). It should be noted that further studies, including data analysis and
clinical validation of functions and probability estimates used in our models in this chapter,
are ongoing. However, the types of optimization models we present for the adaptive plan-
ning framework would be applicable in any treatment environment that has similar stages,
namely: make a pre-treatment plan, begin treatment, observe change in the patient or ob-
tain additional patient-specific information, re-plan, and finish treatment. We expect that
these treatment planning approaches will become increasingly applicable as mid-treatment
biomarker measurements and other monitoring of each patient’s status during treatment
become more prevalent.
The two main goals in lung cancer treatment are to eradicate the tumor and spare healthy
organs. Towards the first goal, we consider maximizing the chance of no tumor progression
after 2 years, which we refer to as the probability of local tumor control, PLTC. There
are numerous healthy organs to consider (e.g., spinal cord, esophagus, heart), but the lung
itself necessarily receives radiation. Therefore, in our models we particularly focus on the
adverse effect of radiation-induced lung toxicity (RILT), namely, the probability a patient
will develop RILT of grade 2 or higher, which we denote by PRILT.
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Table 5.1: Parameter estimates for calculating the probability of local tumor control
Parameter Estimate
S0(2) 0.298
β0 5.928
β1 0.0988
a 0.813
5.2.1 Local Tumor Control
The relationship between dose distribution vector z and PLTC can be characterized as
follows: let F (z) be D95 to the PTV (that is, 95% of the PTV receives dose of at least D95);
then
PLTC(z) = S0(2)
eβ0−β1(F (z)) , (5.1)
with parameters S0(2), β0, and β1 (see Table 5.1 for estimates of values of these parameters
and Cox , 1972 for more information on a fitted Cox regression model used to obtain these
estimates). However, due to the computational difficulties presented by incorporating the
functional form of D95 into optimization problems, we will use the linearized EUD function
as a proxy for D95 instead. That is, in our models we will use
F (z) = zEUDPTV ≡ azminPTV + (1− a)z¯PTV, (5.2)
where zminPTV and z¯PTV are the minimum and mean doses to the PTV, respectively, and a is
a structure-specific parameter used in the definition of linearized EUD (Thieke et al., 2002;
see Table 5.1 for the value of a used). Note that, since PLTC is increasing in F (z), z
EUD
PTV can
be maximized instead.
5.2.2 Radiation Induced Lung Toxicity
Higher probability of RILT is the result of higher lung dose, specifically, higher mean lung
dose. Analysis of data collected for a large population of patients suggests the relationship
between mean lung dose and PRILT depicted in Figure 5.1, which is traditionally used to
estimate patient’s PRILT pre-treatment (in view of the following discussion, the relationship
can be interpreted as the expected value of PRILT, as a function of mean lung dose, for a
patient sampled from the population uniformly at random).
Gathering additional information part-way into the treatment can give planners a patient-
specific estimate of the relationship between PRILT and mean lung dose. In particular, our
clinical collaborators have considered the ratio of Transforming Growth Factor β1 (TGFβ1)
level measured 2 weeks into the treatment, and its pre-treatment level (see Kong et al., 2008
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Figure 5.1: Population based dependence of PRILT on mean lung dose (or expected PRILT).
for background information). Let u be the value of 2-week TGFβ1 ratio measured for a
particular patient:
u =
TGFβ12wk
TGFβ10wk
. (5.3)
According to the biostatistical studies by our collaborators, the estimate of PRILT as a func-
tion of dose distribution z (specifically, mean lung dose z¯lung) for this patient can be expressed
as
PRILT(z;u) =
eX(z¯lung;u)
1 + eX(z¯lung;u)
, (5.4)
where
X(z¯lung;u) = γ
2
0 +
(
γ21 + γ
2
2u
)
z¯lung (5.5)
and
z¯lung =
1
|Vlung|
∑
j∈Vlung
zj. (5.6)
(Table 5.2 shows estimates of relevant parameter values.)
Table 5.2: Parameter estimates for PRILT
Parameter Estimate
γ20 -5.3731
γ20 0.1697
γ20 0.0315
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Figure 5.2 depicts the population-based (i.e., expected) PRILT function, as well as two
patient-specific functions, one for a patient whose lung tissue is more resistant (i.e., having
a lower value of u), and anther for a patient whose lung tissue is more sensitive (i.e., having
a higher value of u).
Figure 5.2: PRILT as a function of mean lung dose for the population (expected PRILT) and
for sensitive and resistant patients.
5.2.3 Bounding PRILT in Pre-Treatment Planning Models
Since RILT is a highly undesirable side effect of radiation therapy in lung cancer cases,
it is common to include an upper bound on PRILT in optimization models used for treatment
planning. In light of the above discussion of patient-specific functional forms of PRILT, we
will discuss the meaning of such bounds, and two possible forms they can take. In this
subsection, we discuss the pre-treatment planning setting (i.e., planning done before the
value of u specific to the patient can be observed), but similar ideas are utilized in the
discussion of adaptive models later in this chapter.
Consider planning a treatment for a new patient, before a measurement of TGFβ1 ratio
specific to him can be made. We can view this patient as being selected randomly (uniformly)
from the entire population of patients; thus we can view his TGFβ1 ratio as a random
variable U . We assume that U is a continuous nonnegative random variable, with CDF H(·)
reflecting the distribution of values of this biomarker in the patient population. We consider
two possible approaches to constraining PRILT in our treatment planning models:
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Option 1 (“pop”): population-based, or expected value constraint, stating that expected
PRILT for a given patient does not exceed 1 − α (for a given α ∈ (0, 1)). This constraint is
commonly used in the traditional, non-adaptive approach to treatment planning. Essentially,
this constraint is a bound on the height of the blue curve in Figures 5.1 and 5.2; we can
express it as
E [PRILT (z;U)] ≡
∫
R
PRILT (z;u) dH(u) ≤ 1− α. (5.7)
(5.7) provides an important bound because a clinic is interested in their expected treatment
outcomes for a population of patients. However, due to the nature of an expectation, prob-
ability of RILT in some patients will be higher, in some patients — lower, than the target
value of 1− α, thus, this planning approach is not ideal on a patient-by-patient basis.
Although U is a continuous random variables, for computational tractability we use a
scenario-based discrete approximation. We discretize the range of U into S scenarios, ordered
so that u1 < u2 < . . . < uS−1 < uS (recall that higher values of u indicate higher levels of
patient’s sensitivity to radiation, so u1 corresponds to the most resistant patients, and uS —
to the most sensitive ones), and let ps be the probability of scenario s occurring. Details on
how the scenario set is constructed can be found in Section 5.4.1. With this discretization,
constraint (5.7) can be rewritten as
S∑
s=1
psPRILT (z;u
s) ≤ 1− α. (5.8)
Option 2 (“rob”): robust constraint, stating that PRILT for the given patient does not
exceed 1 − α. The attractive feature of this constraint is that it provides a bound on
the complication probability for the specific patient, which is attractive to clinicians and
planners, as well as patients. However, in pre-treatment planning, without any patient-
specific information available to the planner, this constraint is expressed as
PRILT(z;u) ≤ 1− α ∀u ∈ <, (5.9)
or, using our scenario approximation,
PRILT(z;u
s) ≤ 1− α, s = 1, . . . , S. (5.10)
In other words, without patient-specific information available, this is a worst-case bound on
PRILT for any patient, which leads to rather conservative treatment plans.
93
5.3 Planning Strategies and Models
In this section, we present three treatment planning strategies, formulate corresponding
treatment planning optimization models, and discuss solution approaches.
The first treatment strategy we describe is non-adaptive (NA), which does not consider
future adaptation explicitly and will serve as a baseline for comparison the other two strate-
gies. Currently, the NA strategy is used in most clinics.
The other two treatment strategies incorporate new information (namely, observation
of biomarker value u part-way into the treatment) to allow adaptation, i.e., changing the
remaining portion of the treatment after the observation is made. The stochastic adap-
tive (SA) model uses two-stage stochastic optimization to fully incorporate adaptation of
the treatment plan into the pre-treatment treatment planning model. However, as we will
discuss, the SA model can be expensive to solve. Therefore, modeling strategy approximate
adaptive (AA) was developed to generate high quality “future-conscious” treatment plans
without the heavy computation overhead of the SA model.
We will use the IMRT FMO treatment planning framework in our models, with the same
notation as in Section 1.2.1. To keep our formulations concise, we let Z ⊂ R|V| denote the set
of feasible dose distributions, i.e., ones that satisfy any upper- and lower-bound constraints
and other clinical constraints on the dose distributions to structures other than the lung
and the PTV. We will assume that the set Z is convex, which is commonly true in clinical
settings; in our computational experiments set Z was a convex polyhedron.
5.3.1 Non-adaptive Treatment Planning Models
We begin by presenting the non-adaptive treatment planning models with two options
for constraining PRILT, and exploring relevant mathematical structure of each formulation.
The basic structure of these models is:
(NA) maximize
x,z
PLTC(z)
s.t. z ∈ Z
zj =
∑
i∈N
Dijxi j ∈ V
xi ≥ 0 i ∈ N
constraint on PRILT,
where, as discussed in Section 5.2.3, we have two options for constraining PRILT.
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Option 1: Population-based bound on expected PRILT. In the model (NApop) we use
constraint (5.7) to limit PRILT:
(NApop) maximize
x,z
PLTC(z) (5.11)
s.t. z ∈ Z (5.12)
zj =
∑
i∈N
Dijxi j ∈ V (5.13)
xi ≥ 0 i ∈ N (5.14)
E[PRILT(z, U)] ≤ 1− α (5.15)
Referencing expressions (5.4) and (5.5), we can express the left-hand side of (5.15) as follows:
E [PRILT (z;U)] ≡
∫
R
PRILT(z, U) dH(u)
=
∫
R
eX(z¯lung,u)
1 + eX(z¯lung,u)
dH(u)
=
∫
R
1− 1
1 + eX(z¯lung,u)
dH(u)
= 1−
∫
R
1
1 + eX(z¯lung,u)
dH(u)
= 1−
∫
R
1
1 + eγ
2
0+(γ
2
1+γ
2
2u)z¯lung
dH(u),
and, using an S-scenario discrete approximation, we can express constraint (5.15) as
≈ 1−
S∑
s=1
ps
1 + eγ
2
0+(γ
2
1+γ
2
2u)z¯lung
≤ 1− α.
Notice that the function on the left-hand side is monotone decreasing in z¯lung, and so we can
reduce this constraint to a simple upper bound constraint on z¯lung:
z¯lung ≤ MLD(1), (5.16)
where MLD
(1)
is defined as the solution to
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α =
S∑
s=1
ps
1 + eγ
2
0+(γ21+γ22us)MLD
(1)
, (5.17)
which can be obtained numerically. Moreover, PLTC is a monotone increasing function of
z¯lung, and thus objective function (5.11) can be replaced with z¯lung. Therefore, if Z is a
polyhedral set, (NApop) is a linear programming problem.
Option 2: Robust bound on PRILT. Model (NArob) uses constraint (5.9), or its S-
scenario discretization (5.10) for controlling PRILT:
(NArob) maximize
x,z
PLTC(z) (5.18)
s.t. z ∈ Z (5.19)
zj =
∑
i∈N
Dijxi j ∈ V (5.20)
xi ≥ 0 i ∈ N (5.21)
PRILT(z, u
S) ≤ 1− α. (5.22)
Again, objective function of (NArob) can be replaced with z¯lung, and constraint (5.22) can
be simplified by incorporating expressions (5.4) and (5.5) and rewriting the inequality as
γ20 +
(
γ21 + γ
2
2u
S
)
z¯lung ≤ ln
(
1− α
α
)
,
further simplified to
z¯lung ≤
ln
(
1−α
α
)− γ20
γ21 + γ
2
2u
S
. (5.23)
5.3.2 Framework for Adaptive Treatment Planning Models
In this subsection we present several adaptive treatment planning models. To recap, the
general framework for these models is as follows: an initial treatment plan is developed prior
to observation of any patient-specific information captured by the TGFβ1 ratio. Treatment
delivery proceeds based on this plan, using equal fractions, until patient-specific information
(i.e., the value of the biomarker u) is observed (we refer to this as “stage 1” of the treatment).
At this point, the treatment is adapted, based on the dose delivered so far and the observed
value of u, and the remainder (“stage 2”) of the treatment is performed using the updated
plan.
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We will use the following additional notation: we define superscripts (1) and (2) to
designate the two treatment stages discussed above. For example, we will denote by z(1) and
z(2) the dose distributions of the treatment plans obtained for stages 1 and 2 of the treatment,
respectively (with x(1) and x(2) denoting the vectors of corresponding beamlet intensities).
Let w ∈ (0, 1) denote the length of the first stage, specifically, the percentage of treatment
that elapses before u is observed. Then, the patient receives a total dose distribution of
wz(1) in stage 1 of the treatment, (1 − w)z(2) — in stage 2, and a total distribution of
wz(1) + (1− w)z(2).
5.3.3 Stochastic Adaptive Treatment Planning Models
This section presents model SA for adaptive treatment planning (with two options for
constraining PLTC) based on the standard two-stage stochastic programming approach. The
advantage of this approach is that treatment planning for the first stage incorporates second-
stage treatment adaptation into the model. In other words, the first stage treatment plan
produced by SA is calculated in an informed way, which should enable it to take better
advantage of the re-planning opportunities than any other model. (See Shapiro et al. (2014)
for more information on stochastic programming.)
As before, we use a scenario-based approximation of the distribution of U in these models.
The basic structure of SA models is:
(SApop)
maximize
x(1), z(1), x(2)(s),
z(2)(s), z(s), s=1,...,S
S∑
s=1
psPLTC(z(s))
s.t. z
(1)
j =
∑
i∈N
Dijx
(1)
i j ∈ V
z
(2)
j (s) =
∑
i∈N
Dijx
(2)
i (s) j ∈ V ; s = 1, . . . , S
zj(s) = wz
(1)
j + (1− w)z(2)j (s) j ∈ V ; s = 1, . . . , S
constraint on PRILT
z(1) ∈ Z(1)
z(2)(s) ∈ Z(2) s = 1, . . . , S
z ∈ Z
x
(1)
i ≥ 0 i ∈ N
x
(2)
i (s) ≥ 0 i ∈ N, s = 1, . . . , S.
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The additional notation in this model includes x(2)(s) and z(2)(s) for s = 1, . . . , S — the
beamlet intensities and dose distribution, respectively, to be used in the second stage of
the treatment if the biomarker value us is realized, as well as the corresponding total dose
distribution z(s), for s = 1, . . . , S. Also, because of the explicit incorporation of biomarker
realizations, we alter our objective function to be the expectation of PLTC. This objective
function is separable in F (z(s)) and concave when the probability of complication exceeds
1− e−1 ≈ 63.2% (see Appendix B for derivation).
As in the (NA) models, we have two options for constraining PRILT in (SA).
Option 1: Population-based bound on expected PRILT. In the model (SApop) we use
a constraint similar to (5.7) to limit PRILT, with the modification reflecting scenario-based
values z¯lung(s) incorporated into the expectation:
(SApop)
maximize
x(1), z(1), x(2)(s),
z(2)(s), z(s), s=1,...,S
S∑
s=1
psPLTC(z(s)) (5.24)
s.t. z
(1)
j =
∑
i∈N
Dijx
(1)
i j ∈ V (5.25)
z
(2)
j (s) =
∑
i∈N
Dijx
(2)
i (s) j ∈ V ; s = 1, . . . , S
(5.26)
zj(s) = wz
(1)
j + (1− w)z(2)j (s) j ∈ V ; s = 1, . . . , S
(5.27)∑
s=1,...,S
PRILT(z(s);u
s)ps ≤ 1− α (5.28)
z(1) ∈ Z(1) (5.29)
z(2)(s) ∈ Z(2) s = 1, . . . , S (5.30)
z ∈ Z (5.31)
x
(1)
i ≥ 0 i ∈ N (5.32)
x
(2)
i (s) ≥ 0 i ∈ N, s = 1, . . . , S.
(5.33)
Constraint (5.28) can be written as follows:
S∑
s=1
ps
1 + eγ
2
0+(γ21+γ22us)z¯lung(s)
≥ α. (5.34)
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The left hand side of this constraint is decreasing in z¯lung(s) and concave as long as z¯lung(s)
corresponds to a PRILT less than 50% (see appendix B for derivation).
Option 2: Robust bound on PRILT. Model (SArob) imposes the robust version of the
constraint on PRILT:
(SArob)
maximize
x(1), z(1), x(2)(s),
z(2)(s), z(s), s=1,...,S
S∑
s=1
psPLTC(z(s)) (5.35)
s.t. z
(1)
j =
∑
i∈N
Dijx
(1)
i j ∈ V (5.36)
z
(2)
j (s) =
∑
i∈N
Dijx
(2)
i (s) j ∈ V ; s = 1, . . . , S (5.37)
zj(s) = wz
(1)
j + (1− w)z(2)j (s) j ∈ V ; s = 1, . . . , S (5.38)
PRILT(z;u
s) ≤ 1− α s = 1, . . . , S (5.39)
z(1) ∈ Z(1) (5.40)
z(2)(s) ∈ Z(2) s = 1, . . . , S (5.41)
z ∈ Z (5.42)
x
(1)
i ≥ 0 i ∈ N (5.43)
x
(2)
i (s) ≥ 0 i ∈ N, s = 1, . . . , S.
(5.44)
Constraint (5.39) can be expressed as simple upper bounds on z¯lung(s):
z¯lung(s) ≤
ln
(
1−α
α
)− γ20
γ21 + γ
2
2u
s
s = 1, . . . , S. (5.45)
5.3.3.1 Second Stage Planning Strategies
With the SA model, second-stage dose distributions, z(2)(s) are found for S specific
biomarker ratio observations. However, the observed biomarker ratio u may, and is most
likely, not one of these values. Therefore, the second stage dose distributions found in (SA)
may not correspond precisely to a patient’s estimated predisposition to PRILT. Physicians
must find a suitable second stage dose distribution for the patient. Two common strategies
exist for selecting a second stage treatment plan. Physicians can use the pre-computed second
stage treatment plan (x(2)(s), z(2)(s)) with scenario s that corresponds to the observed value
of u (see Section 5.4.1 for more details on matching u with s), or they can use a patient-
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specific plan found by reoptimizing the second stage dose specific to the observed ratio u.
This replanning model is presented below.
Let z¯ denote the dose distribution used in the first stage of the treatment (i.e., at the
time of re-planning, wz¯ has been already delivered to the patient), and u denote the observed
value of the biomarker. The corresponding instance of the re-planning problem (RP(z¯, u))
calculates the second-stage dose z(2) and total dose z = wz¯ + (1− w)z(2):
(RP(z¯, u)) maximize
x˜(2),z(2),z
PLTC(z) (5.46)
s.t. z ∈ Z (5.47)
z
(2)
j =
∑
i∈N
Dijx
(2)
i j ∈ V (5.48)
x
(2)
i ≥ 0 i ∈ N (5.49)
zj = wz¯j + (1− w)z(2)j j ∈ V (5.50)
PRILT(z, u) ≤ 1− α (5.51)
Due to the patient-specific nature of replanning model, constraint (5.51) of (RP) bounds
PRILT for the particular observed value of u. This constraint’s algebraic form is similar to
(5.23).
It should be noted that the (SApop) model may allow PRILT(z(s);u
s) to exceed 1 − α
for some scenarios. Using the pre-computed second stage dose distributions may result in
patients with higher than 1−α probabilities of PRILT. This characteristic can be seen in the
results Section 5.4.3.
5.3.4 Approximate Adaptive Treatment Planning Model
While the SA model offers the most control over PRILT and explicitly incorporates multiple
potential stage 2 biomarker realizations into the pre-treatment planning, its solution time
may prove clinically prohibitive in practice (see Table 5.4 for run time and problem size
details for our application). As S increases, the stochastic model solve time increases to
multiple hours, a time too long for practical clinical use.
In light of this, we also consider a simpler model for first-stage treatment planning in the
adaptive framework. This model approximates the stochastic programming model (we refer
to it as the approximate model, or AA). In particular, in this model we deliberately avoid
the creation of a second-stage dose distribution z(2)(s) for each scenario (which makes the
(SA) models large and hard to solve). Instead, we use a singe variable z(2) to approximate
eventual second-stage treatment decisions, imposing a number of constraints to encourage a
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good approximation.
The approximate adaptive model is as follows:
(AArob) maximize
x˜(1), z˜(1), x(2),
z(2), z
PLTC(z) (5.52)
s.t. z ∈ Z (5.53)
z˜
(1)
j =
∑
i∈N
Dijx˜
(1)
i j ∈ V (5.54)
x˜
(1)
i ≥ 0 i ∈ N (5.55)
z
(2)
j =
∑
i∈N
Dijx
(2)
i j ∈ V (5.56)
x
(2)
i ≥ 0 i ∈ N (5.57)
zj = wz˜
(1)
j + (1− w)z(2)j j ∈ V (5.58)
PRILT(z˜
(1), uS) ≤ 1− α (5.59)
PLTC(z˜
(1)) ≥ PLTC(z∗)−  (5.60)
PRILT(z, u
1) ≤ 1− α. (5.61)
Variables x˜(1) and z˜(1) represent the first stage beamlet intensities and dose distribution,
respectively, produced by this model, and variables x(2) and z(2) are approximations of second
stage treatment decisions. It should be noted that the size of this problem is independent of
S.
Constraints (5.59) and (5.60) ensure that the first stage dose distribution is no worse
than the one obtained by solving (NArob) (here, z
∗ denotes the optimal value of (NArob)).
Since the model (AArob) has limited foresight into second-stage treatment, we utilized the
robust option for bounding PRILT, to ensure that there will exist a second-stage treatment
plan for each patient that is safe, i.e., has PRILT that does not exceed 1−α regardless of this
patient’s u value. We allow a small deviation, , from the optimal value z∗ to avoid numerical
issues without sacrificing plan quality by any significant amount. Constraint (5.61) allows
the second stage dose distribution to push more dose into the lung given the initial stage
one dose distribution, leading to a first-stage treatment plan (z(1), x(1)) that will allow for a
more flexible plan adaptation.
Because only the extremes of the biomarker ratio range are considered, we would solve
(RP(z˜(1), u)) to get the second stage treatment plan specific to this patient after delivering
dose wz˜(1) to the patient and observing u.
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5.4 Results and Discussion
In the previous section, we introduced 5 models for treatment planning: two non-adaptive
models, (NApop) and (NArob), and three models for computing treatment plans in an adaptive
environment, (SApop), (SArob), and (AArob).
These models were tested on four clinical lung cancer cases. The size of the data for
each case can be seen in Table 5.3. These cases were selected out of a pool of lung cancer
patients for their flexibility in allowing higher doses to the lung while staying within other
organs’ dosimetric limits. We are interested in the tradeoff between PRILT and PLTC. In this
section, we would like to show that the different models generate different first-stage dose
distributions, and that these distributions have an impact on the tradeoff between PRILT and
PLTC in the resulting full treatment.
Table 5.3: The sizes of clinical cases: number of voxels and number of beamlets. The
clinical number is the identifier for the case in UMPlan, the University of Michigan’s in-
house treatment planning system, included here for figure references and in case data needs
to be retrieved.
Case Clinical number |V| |N|
1 38 20221 1184
2 44 14965 1388
3 45 15155 1411
4 49 19473 1270
Table 5.4: The number of variables, constraints, and non-zeros as well as run time ranges in
minutes for case 3.
Model Variables Constraints Non-zeros Time min Time max
(NArob) 16572 17651 17871794 2 5
(SApob), S= 2 80029 83664 53702943 85 130
(SArob), S= 2 80027 83574 53702763 40 110
(AA
(1)
rob) 48299 50457 35789053 8 50
(SApob), S= 4 143487 149695 89538301 130 170
(SArob), S= 4 143483 149498 89537905 120 180
Throughout Section 5.3, we discussed the specific mathematical structure of PLTC and
PRILT-related functions used in the objectives and constraints of our models. Although in
many cases we could simplify these functions and constraints to be linear, a few remaining
functions are still nonlinear, notably, the objective function of both (SA) models and the
population-based PRILT constraint in the model (SApob). In our computational work, we
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approximated these nonlinear functions using inner piecewise linear approximations within
their convex regions at 1 Gy spacing on the x-axis. These approximation techniques are
discussed in Appendix C, which contains the full linear programming formulation of the
stochastic adaptive models from Section 5.3.3. This enabled us to use an off-the-shelf linear
program solver for this project. Due to the proof-of-concept nature of this chapter, we believe
it is sufficient to use a general purpose solver (in particular, clinical solution times are not
directly considered in this project).
5.4.1 Discretizing the Biomarker Ratio Distribution
As mentioned in Section 5.2.2, the random variable U is a continuous random vasriable,
whose distribution can be estimated using a (finite) set of already-treated patients. How-
ever, the full set of patient outcomes cannot be integrated into the stochastic model in a
computationally tractable way; thus we used a partitioning of the domain of U into potential
scenarios s = 1, . . . , S, with a single value, us, representing each scenario. We partitioned
the range of observed values of TGFβ1 ratios into S intervals, and chose the largest value in
each interval to be the “representative” value. Recall that larger values of u are observed in
patients who are more sensitive to radiation; this choice of representative values allows us to
provide robust guarantees on PRILT even using the scenario-based modeling approach. This
guarantee holds when we select a pre-computed second stage dose distribution from (SA) to
deliver to a patient after u is observed.
When it came to the choice of intervals to cover the domain of U , we considered a quantile
partition strategy and a uniform partition strategy.
Quantile Strategy Given the desired cardinality S, each scenario s corresponds to the
appropriate quantile of the underlying distribution of patient TGFβ1 ratios. Since the
distribution is divided by quantiles, ps = 1/n for each s = 1, . . . , S.
Uniform Strategy The domain of TGFβ1 ratios is split into S intervals of equal length.
The probability of a realization falling into the interval S is then:
ps =
|S(s)|∑S
s′=1 |S(s′)|
, (5.62)
where |S(s)| is the number of ratio realizations in interval s in the underlying data set.
After speaking with clinical collaborators and seeing little difference in the performance
of these partitioning strategies, we continue the chapter using only the quantile strategy.
Table 5.5 shows the us values for the n-quantile strategy. We artificially imposed 4.5 as
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the maximum value in order to keep a few outliers from the true distribution from overly
influencing the model.
Table 5.5: Scenario-specific biomarker ratio realizations for different numbers of quantiles
1-quantile 2-quantile 3-quantile 4-quantile 5-quantile
u0 4.5 0.795323131 0.576232926 0.503458878 0.4182977484
u1 4.5 1.069878213 0.795323131 0.6559276511
u2 4.5 1.4 0.8919406165
u3 4.5 1.5589825295
u4 4.5
5.4.2 Sanity Check: Flexibility in stage-one dose distribution
First, we determine if different models generate different z(1) dose distributions for stage 1
of the treatment (for non-adaptive models, obviously, stage 1 and stage 2 dose distributions
are the same). Dropping the superscript (1) for the purposes of this comparison, let us
consider zNArob − zAArob and zNArob − zSArob. The elements of these difference vectors are sorted in
increasing order and displayed for the PTV and lung structures in Figure 5.3. We can see
that there is a significant amount of dose redistribution.
5.4.3 Analysis for a Two-scenario Patient Population
Suppose that a patient can only have two biomarker ratio realizations that correspond
to the 2-quantile discretization presented in Section 5.4.1. We will relax this assumption
later on and consider the entire biomarker ratio distribution, but as a proof of concept, let
us consider this simple case. Because these biomarker ratio realizations are far apart, they
can be seen as a patient either being resistant to radiation (u = 0.795323131), or sensitive
to radiation (u = 4.5).
In this two-scenario environment, we do not solve model (RP(z¯, u)) to get a stage 2 dose
distribution with a robust bound (i.e., a stage 2 dose distribution with PRILT bounded by
constraint (5.51)). Instead, we consider the stage 2 dose distributions as determined by the
pre-treatment models to highlight the differences in PRILT control. Clinically, provided there
are available resources, model (RP(z¯, u)) could be solved to determine the patient-specific
stage 2 dose distribution. With only two scenarios, it is sufficient for the AA model to use
the overall dose distribution z = wz(1) +(1−w)z(2) for the resistant patient and stage 1 dose
distribution z˜(1) for the sensitive patient (from model (AArob)).
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Figure 5.3: Sorted differences in first-stage dose distribution vectors (a) zNArob − zAArob lung, (b)
zNArob − zAArob PTV, (c) zNArob − zSArob lung, and (d) zNArob − zSArob PTV.
It is interesting to analyze what is considered to be a feasible range of mean lung doses for
sensitive and resistant patients in different pre-treatment models. For example, in (NArob) the
treatment is planned assuming the patient is sensitive. On the other hand, the (SA) models
would optimize for both the initial dose distribution and the distributions corresponding to
the potential biomarker ratio realizations, with population (or expected value) based model
allowing for more flexibility than the robust (or worst-case) model. The different overall
mean lung dose feasible regions can be found in Figure 5.4.
Another key insight we want to look at is the tradeoff between PRILT and PLTC for
the patient population, as well as for sensitive and resistant patients, for each value of α.
Consider the tradeoff curves for case 2 in Figures 5.5, 5.6, and 5.7 that compare the realized
PRILT and PLTC for each patient type (as well as the population averages) if treated with
the plans obtained from models (NA) and (SA). (Recall that scenario 1 represents resistant
patients, and scenario 2 — sensitive patients.) Connecting black lines show the points on the
curve corresponding to a particular α. These connecting lines are vertical for the stochastic
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Figure 5.4: Feasible region with respect to mean lung dose for the second stage dose distri-
bution for the different methods (WC Bound = “rob” strategies)
adaptive robust method (i.e., the PRILT bound is kept and additional dose is added to raise
the PLTC), and these lines are horizontal for the non-adaptive method (i.e., the overall dose
stays the same and only the PRILT changes based on patient sensitivity). We see that both
techniques produce realizations that are on similar curves, but how these are related differ
greatly. Consider PRILT being bounded at 15%. Table 5.6 shows the realized values for each
of the techniques (recall, without solving model (RP(z¯, u))). We see that the added flexibility
in the stochastic adaptive model with population bound gives us the best population-wide
average PLTC, but it comes at the expense of the sensitive patient receiving more dose. We
also see that the approximate adaptive methodology performs almost as well as the stochastic
adaptive robust model, with much less computational overhead. The approximate adaptive
method performs similarly to the stochastic adaptive robust model in Figure 5.7, and thus
is not shown separately. Figures 5.5, 5.6, and 5.7 show the same plots for case 4.
5.4.4 The Impact of Treatment Adaptation to Exact Biomarker Value, and of
Adaptation Timing
Having demonstrated the potential structural impact of treatment re-planning on patient
outcomes in the previous subsection, let us consider more realistic measurements of biomarker
values: after w percent of the treatment has been delivered, an exact biomarker value is
observed; in particular, we no longer crudely partition the population into “sensitive” and
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Figure 5.5: PRILT vs. PLTC for a two-scenario patient population, case 2, NA - pop and rob
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Figure 5.6: PRILT vs. PLTC for a two-scenario patient population, case 2, SA - pop
“resistant” patients, but consider the full continuous range of potential biomarker values.
Out of necessity, the formulations of (SA) models are still scenario-based, and second-
stage treatment decisions (x(2)(s), z(2)(s)) for biomarker values us, s = 1, . . . , S included
in the models are produced in the process of obtaining first-stage solutions. As mentioned
in Section 5.3.3.1, when the precise value of u is observed, the treatment planner faces a
choice: to invest the time and create a second-stage treatment plan from scratch by solving
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Figure 5.7: PRILT vs. PLTC for a two-scenario patient population, case 2, SA - rob
Table 5.6: Realized PRILT and PLTC for α = 0.85
PRILT PLTC
Resis. Sens. Average Resis. Sens. Average
Non-adaptive - rob 0.0432 0.15 0.0966 0.6225 0.6225 0.6225
Non-adaptive - pop 0.0608 0.2392 0.15 0.7202 0.7202 0.7202
Approx Adaptive - rob 0.15 0.15 0.15 0.8378 0.6225 0.7301
Stochastic - rob 0.15 0.15 0.15 0.8384 0.6225 0.7304
Stochastic - pop 0.1034 0.1963 0.15 0.8079 0.6827 0.7453
an instance of problem (RP), or to utilize the pre-computed second stage treatment plan
(x(2)(s), z(2)(s) with scenario s that corresponds to the observed value of u (see Section 5.4.1).
Suppose the treatment planner decides to use the latter approach, i.e., not to fine-tune
the second stage of the treatment based on the exact observed value of u. Figure 5.11 shows
resulting treatment outcomes (PRILT and PLTC ) as a function of the patient’s biomarker
value. (The (SA) models were solved with S = 4 quantile-based scenarios). The figure
shows that there are benefits to be gained over non-adaptive treatments even when using
this limited version of treatment adaptation: more dose is given to the patients who are
identified as being more resistant, leading to improved PLTC.
Next, let us study the treatments resulting from full re-planning to the exact observed
biomarker value. We will focus our attention on the robust (option 2) treatment planning
models. The results can be seen in Figure 5.12. These lines are essentially on top of each
other. We see that the flexibility of the treatment planning optimization model, clinical pro-
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Figure 5.9: PRILT vs. PLTC for a two-scenario patient population, case 4, SA - pop
tocol, specific case geometry, and choice of w allow us to perform well regardless of the dose
distribution. As mentioned before, these cases were chosen for their flexibility in planning
(i.e., tumor is position relatively far from organs at risk). While this can be considered wor-
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Figure 5.10: PRILT vs. PLTC for a two-scenario patient population, case 4, SA - rob
risome for these techniques (i.e., little benefit gained from solving more complicated models
when model (RP(z, u)) is used), not all treatment plans will be as forgiving.
Sometimes not all of these flexibility-generating elements occur and an informed initial
stage distribution offers significant benefits. One example of when an informed approach
leading into reoptimization is desirable is when w is large (i.e., reoptimization occurs closer
to the end of treatment). Consider the non-adaptive method and the approximate adaptive
method. As a proof of concept, the initial treatment plan was developed for u = 4.5 and
then adapted to a realized biomarker ratio of u = 0.795323131 with w = 0.33, 0.67, 0.90, 0.95.
We assume that the accuracy of the biomarker-informed PRILT relationship does not change
based on w for this example.
As we see in Figure 5.13, as w is increased, the impact of the initial dose distribution
increases as well. There are two main takeaways from these plots. First, it is better to
test earlier than later. This intuitively makes sense as we have more room for adapting
the treatment. Second, the approximated adaptive methodology’s initial dose distribution
is better for replanning and allows for more flexibility as w increases.
5.4.5 When to Use These Techniques
The need for these techniques occurs frequently in the clinic. Treatment planners should
use a technique when adaptation is likely, as the choice of initial dose distribution will
likely have some kind of an impact on the flexibility of adapting the plan. For example,
esophagitis often occurs when treating lung cancer patients. If the patient’s symptoms get
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Figure 5.11: (top) Treatment outcomes for non-adaptive plans, and plans with limited
(scenario-based only) adaptation, vs. patient’s biomerker value; Realized PRILT (top) and
PLTC (bottom) realized.
too extreme during the treatment, the patient is replanned to spare the esophagus. Without
proper preparation in the treatment planning process, the patient may experience even more
adverse effects or subpar tumor coverage. If adaptation is not likely to be forced to occur
due to complications, then it might be useful to plan for “boosting” the dose near the end
of treatment if the patient is responding well to the radiation. In most cases, and especially
when w is not clearly known, we recommend the approximate adaptive methodology.
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Figure 5.12: For w = 0.33, (left) realized PRILT vs. biomarker ratio realization for reoptimized
plans, (right) realized PLTC vs. biomarker ratio realization for reoptimized plans; all models
on nearly the same lines
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Figure 5.13: PRILT vs. PLTC for w= (a) 0.33, (b) 0.67, (c) 0.90, and (d) 0.95
5.5 Conclusions and Future Research
In conclusion, the initial stage dose distribution has an important effect on the quality of
the adapted dose distribution. Without some kind of methodology in place to address this
issue, treatment planners could produce subpar treatment plans when they adapt to changes
in patient information. This methodology can be extended to handle multiple potential
adaptations and “future proof,” to a degree, a plan that is likely to be adapted.
One assumption that was made in this work was that the functions representing PRILT
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were certain and that the biomarker ratio realizations were exactly representative the pa-
tient’s true sensitivity to radiation. That is, there was no uncertainty around the probability
functions or biomarker ratio realizations incorporated into the models. A natural extension
to this work is to consider the probability functions and/or the biomarker ratio realization
as estimates and incorporate the associated uncertainty to the treatment planning model.
Another extension to the model could be made when considering the timing of replanning,
i.e., the value of w. Suppose that there are only enough clinical resources to adapt a patient’s
treatment to new information exactly once. Also suppose that the information you obtain
from testing the patient (e.g., a biomarker test) increases in accuracy as w increases. Waiting
to get better information competes with the notion from Section 5.4.4 that more adaptive
flexibility is gained by obtaining information earlier. In these models, treatment planners
would need to decide pre-treatment when is the best time gather new information and adapt,
w, and how to plan knowing that adaptation will occur.
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APPENDIX A
Extending the Feasible Aperature Region by
Restricting Gantry Travel Time
We can consider a family of potential choices for Ak¯k`,k`+1 . Let Ak¯k`,k`+1(t) be defined as
the following equation with fixed angular speed t.
Ak¯k`,k`+1(t) =
{
A ∈ A : tδk` ≥ TLk`,k¯(Ak` , A), tδk¯ ≥ TLk¯,k`+1(A,Ak`+1)
}
for tδk¯ ≤ TUk¯ , tδk` ≤ TUk` (A.1)
Clearly, Ak¯k`,k`+1(t) ⊆ Ak¯k`,k`+1(t′) for t ≤ t′ and Ak¯k`,k`+1(TUk`) = Ak¯Uk`,k`+1 is the largest set.
This information will be used when determining the potential MLC leaf arrangements when
solving the pricing problem. One thing to note is that the choice of Ak¯k`,k`+1 ⊆ Ak¯Uk`,k`+1 will
influence the behavior of the algorithm in later stages. If we choose a smaller set Ak¯k`,k`+1 ,
that will result in less flexibility in the current set of apertures, but may allow for greater
flexibility in later stages.
We want to know explicitly how our selected angular travel time t and preceding and
following apertures k` and k`+1 control the feasible aperture region. That is, for each row,
we would like to determine the feasible MLC leaf positions given s, k`, and k`+1 for potential
control point k¯.
Let us assume that t, k`, and k`+1 are fixed along with apertures Ak` , and Ak`+1 . We
would like to know the feasible MLC leaf positions for apertures at control point k¯. First, let
Ak¯r be the rth row of aperture Ak¯. Then, we can define set Ak¯r(t) as the set of feasible rows
for the rth row of control point k¯ with some abuse of notation for in our time constraint.
Ak¯r(t) =
{
a : tδk` ≥ TLk`,k¯(Ak`r, Ak¯r), tδk¯ ≥ TLk¯,k`+1(Ak¯r, Ak`+1r)
}
(A.2)
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Let v be the maximum speed an MLC leaf can move and N be the rightmost leaf setting.
The total distance a leaf can cover is v times the time it is moving. Therefore, we can see
the following relationship.{
a : tδk` ≥ TLk`,k¯(Ak`r, Ak¯r)
}
= {(L,R) : 0 ≤ L ≤ R ≤ N ;
|L− Lk` |, |R−Rk` | ≤ vTt(k`, k¯)
}
(A.3)
We can define the leaf positions in the following manner.
Ak¯r(t) = {(L,R) : 0 ≤ L ≤ R ≤ N ; |L− Lk` |, |R−Rk` | ≤ vTt(k`, k¯);
|L− Lk`+1|, |R−Rk`+1 | ≤ vTt(k¯, k`+1)} (A.4)
This family of apertures is an easy extension to combat greediness when solving the
pricing problem.
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APPENDIX B
Derivations for PRILT and PLTC
PRILT derivation
Consider constraint (5.34) reproduced below:
S∑
s=1
ps
1 + eγ
2
0+(γ21+γ22us)z¯lung(s)
≥ α.
We will show that the left hand side of (5.34) is decreasing in z¯lung(s) and concave as
long as z¯lung(s) corresponds to a PRILT less than 50%.
We can rewrite this complicating constraint as the following:
S∑
s=1
ps
1 + eδ
s
1z
s−δ0 ≥ α, (B.1)
where, for convenience, we have
δ0 = −γ20 (B.2)
δs1 = γ
2
1 + γ
2
2u
s (B.3)
zs = z¯lung(s). (B.4)
We expect that δ0, δ1 > 0 (the initial parameter estimates show have γ
2
0 < 0, γ
1
2 , γ
1
2 > 0).
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Now consider the following function:
f s(zs) =
1
1 + eδ
s
1z
s−δ0 . (B.5)
It is easy to see that this function is decreasing in zs. Moreover,
lim
zs↓−∞
= 1 (B.6)
f s(0) =
1
1 + e−δ0
(B.7)
f s
(
δ0
δs1
)
=
1
2
(B.8)
lim
zs↑∞
= 0, (B.9)
where the first is clinically irrelevant but helps understand the shape of the function.Consider
the solution to the following:
1
1 + eδ
s
1z
s−δ0 = α, (B.10)
which is a feasible solution to the patient-specific strategy. In particular, this yields:
z¯lung(s) =
ln
(
1−α
α
)
+ δ0
δs1
. (B.11)
Suppose α = 0.85; then for us = 0 this is at 21.4 Gy, and for us = 5 this is at 11.1 Gy.
These would correspond to bounds on the mean lung dose that correspond to a particular
PRILT for a given biomarker realization. Now, consider the point zˆ
s ≡ δ0/δs1 = 5.370.17+0.031us Gy.
This point is an inflection point. For us = 0 this is at 31.7 Gy, and for us = 4.5 this is at 17.4
Gy. The constraint function is concave whenever zs ≤ zˆs for all s = 1, . . . , S. This means
that the function is concave on the feasible region as long as we assume that no patient gets
a MLD that would increase their probability of RILT to 1
2
or more. Restricting PRILT to
50% is a clinically reasonable hard bound for RILT. Because the complicating constraint
function is not linear or quadratic, linear program (LP) solvers (such as Gurobi or CPLEX)
cannot handle it directly. However, note that it is separable in zs. Therefore, it is easy to
approximate by a piecewise-linear function as long as we limit ourselves to a part of the
function where it is concave. We do this by having a hard bound on PRILT in all models
where this might be violated (i.e., PRILT(z, u) ≤ 12 for all dose distributions) included in the
construction of dose distribution set Z.
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PLTC derivation
Consider presented stochastic adaptive objective function presented in Section 5.3.3 with
PLTC function from 5.2.1 reproduced below. We will show that this function is separable in
F (z(s)) and concave when the probability of complication exceeds 1− e−1 ≈ 63.2%.
S∑
s=1
psPLTC (z(s)) =
S∑
s=1
psS0(2)
eβ0−β1F (z(s)) (B.12)
While we would like F (z) to be D95 (a dose-volume function), we instead use some kind
of proxy function to facilitate the solving of the optimization model. We let F (z) be a
linearized EUD:
F (z) = azminPTV + (1− a)z¯PTV (B.13)
zminPTV = min
j∈VPTV
zj (B.14)
z¯PTV =
1
|VPTV|
∑
j∈VPTV
zj, (B.15)
with function parameter estimates S0(2) = 0.298, β0 = 5.928, and β1 = 0.0988. Note that
the objective function is separable in F (z(s)). Now let
f(d) = 1− S0(2)eβ0−β1d = exp
(
lnS0(2) · eβ0−β1d
)
, (B.16)
(i.e., f(d) represents probability of local progression (which we want to minimize) and 1−f(d)
is probability of no local progression) where d = F (z). Then its derivative is the following:
f ′(d) = exp
(
lnS0(2) · eβ0−β1d
) · lnS0(2) · β1 · eβ0−β1d < 0. (B.17)
Since 0 < S0(2) < 1, f is decreasing in d. Moreover, its second order derivative is the
following:
f ′′(d) = −β21 · lnS0(2) · eβ0−β1d · exp
(
lnS0(2) · eβ0−β1d
) · [lnS0(2) · eβ0−β1d + 1] . (B.18)
This means that f ′′(d) > 0 and hence f is convex in w whenever satisfies the following:
lnS0(2) · eβ0−β1d + 1 > 0, (B.19)
or, equivalently,
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F (z) = d >
β0 − ln
[
1
ln(1/S0(2))
]
β1
, (B.20)
and concave in d otherwise. This lower bound on F (z) is added to our models as a constraint
in feasible dose distribution set Z presented in Section 5.3. Clinically, plans would not be
allowed to have this low of F (z), so adding a clinically reasonable bound to maintain a
desirable model structure will not impact treatment plan quality.
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APPENDIX C
Full Linear Models for Stochastic Adaptive Lung
Formulations
Option 1: Population-based bound on expected PRILT. The following model is the
LP formulation of the (SApop) model including the piecewise linear approximations.
(SALPpop) maximize
x(1), z(1), x(2)(s), z(2)(s),
z(s), h1s, h
2
s, s=1,...,S
S∑
s=1
psh
1
s (C.1)
subject to
z
(1)
j =
∑
i∈N
Dijx
(1)
i j ∈ V (C.2)
z
(2)
j (s) =
∑
i∈N
Dijx
(2)
i (s) j ∈ V ; s = 1, . . . , S (C.3)
zj(s) = wz
(1)
j + (1− w)z(2)j (s) j ∈ V ; s = 1, . . . , S (C.4)
zminPTV(s) ≤ zj(s) j ∈ VPTV; s = 1, . . . , S (C.5)
z¯PTV(s) =
1
|VPTV|
∑
j∈VPTV
zj(s) s = 1, . . . , S (C.6)
zEUDPTV (s) = az
min
PTV(s) + (1− a)z¯PTV(s) j ∈ VPTV; s = 1, . . . , S (C.7)
z¯lung(s) =
1
|Vlung|
∑
j∈Vlung
zj(s) s = 1, . . . , S (C.8)
zEUDPTV (s) >
β0 − ln
[
1
ln(1/S0(2))
]
β1
s = 1, . . . , S (C.9)
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S∑
s=1
psh
2
s ≥ α (C.10)
h1s ≤ H1
(
zEUDPTV (s)
)
s = 1, . . . , S (C.11)
h2s ≤ H2s (z¯lung(s)) s = 1, . . . , S (C.12)
z(1) ∈ Z(1) (C.13)
z(2)(s) ∈ Z(2) s = 1, . . . , S (C.14)
z(s) ∈ Z s = 1, . . . , S (C.15)
x
(1)
i ≥ 0 i ∈ N (C.16)
x
(2)
i (s) ≥ 0 i ∈ N ; s = 1, . . . , S, (C.17)
where H1(z) is a piecewise-linear and concave function and H2s (z¯lung(s)), for s = 1, . . . , S, is
a piecewise-linear and concave function that satisfy the following:
H1(z) ≈ S0(2)eβ0−β1z (C.18)
H2s (z¯lung(s)) ≈
1
1 + eγ
2
0+(γ21+γ22us1)z¯lung(s)
s = 1, . . . , S. (C.19)
Option 1: Robust bound on PRILT. The following model is the LP formulation of the
(SArob) model including the piecewise linear approximations.
(SALProb) maximize
x(1), z(1), x(2)(s), z(2)(s),
z(s), h1s, h
2
s, s=1,...,S
S∑
s=1
psh
1
s (C.20)
subject to
z
(1)
j =
∑
i∈N
Dijx
(1)
i j ∈ V (C.21)
z
(2)
j (s) =
∑
i∈N
Dijx
(2)
i (s) j ∈ V ; s = 1, . . . , S (C.22)
zj(s) = wz
(1)
j + (1− w)z(2)j (s) j ∈ V ; s = 1, . . . , S (C.23)
zminPTV(s) ≤ zj(s) j ∈ VPTV; s = 1, . . . , S (C.24)
z¯PTV(s) =
1
|VPTV|
∑
j∈VPTV
zj(s) s = 1, . . . , S (C.25)
zEUDPTV (s) = az
min
PTV(s) + (1− a)z¯PTV(s) j ∈ VPTV; s = 1, . . . , S (C.26)
z¯lung(s) =
1
|Vlung|
∑
j∈Vlung
zj(s) s = 1, . . . , S (C.27)
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zEUDPTV (s) >
β0 − ln
[
1
ln(1/S0(2))
]
β1
s = 1, . . . , S (C.28)
h1s ≤ H1
(
zEUDPTV (s)
)
s = 1, . . . , S (C.29)
z¯lung(s) ≤
ln
(
1−α
α
)− γ20
γ21 + γ
2
2u
s
1
s = 1, . . . , S (C.30)
z(1) ∈ Z(1) (C.31)
z(2)(s) ∈ Z(2) s = 1, . . . , S (C.32)
z(s) ∈ Z s = 1, . . . , S (C.33)
x
(1)
i ≥ 0 i ∈ N (C.34)
x
(2)
i (s) ≥ 0 i ∈ N ; s = 1, . . . , S, (C.35)
where H1(z) is a piecewise-linear and concave function that satisfies the following:
H1(z) ≈ S0(2)eβ0−β1z . (C.36)
Note: As long as we limit ourselves to values α > 1
2
then, by construction, the bounds
in (C.10) are uniformly looser than the bounds in (C.30), so that option 2 is indeed more
conservative. We should also make sure to restrict ourselves to values of α that ensure that
the upper bounds (C.30) are nonnegative, i.e.,
α <
1
1 + eγ
2
0
,
which, for our parameter estimates, means α < 0.99538.
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